A	O
nongenomic	O
mechanism	O
for	O
progesterone-mediated	O
immunosuppression	O
:	O
inhibition	O
of	O
K+	B-protein
channels	I-protein
,	O
Ca2+	O
signaling	O
,	O
and	O
gene	O
expression	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

The	O
mechanism	O
by	O
which	O
progesterone	O
causes	O
localized	O
suppression	O
of	O
the	O
immune	O
response	O
during	O
pregnancy	O
has	O
remained	O
elusive	O
.	O

Using	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
we	O
show	O
that	O
progesterone	O
,	O
at	O
concentrations	O
found	O
in	O
the	O
placenta	O
,	O
rapidly	O
and	O
reversibly	O
blocks	O
voltage-gated	B-protein
and	I-protein
calcium-activated	I-protein
K+	I-protein
channels	I-protein
(	O
KV	B-protein
and	O
KCa	B-protein
,	O
respectively	O
)	O
,	O
resulting	O
in	O
depolarization	O
of	O
the	O
membrane	O
potential	O
.	O

As	O
a	O
result	O
,	O
Ca2+	O
signaling	O
and	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
-driven	O
gene	O
expression	O
are	O
inhibited	O
.	O

Progesterone	O
acts	O
distally	O
to	O
the	O
initial	O
steps	O
of	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
-mediated	O
signal	O
transduction	O
,	O
since	O
it	O
blocks	O
sustained	O
Ca2+	O
signals	O
after	O
thapsigargin	O
stimulation	O
,	O
as	O
well	O
as	O
oscillatory	O
Ca2+	O
signals	O
,	O
but	O
not	O
the	O
Ca2+	O
transient	O
after	O
TCR	B-protein
stimulation	O
.	O

K+	O
channel	O
blockade	O
by	O
progesterone	O
is	O
specific	O
;	O
other	O
steroid	O
hormones	O
had	O
little	O
or	O
no	O
effect	O
,	O
although	O
the	O
progesterone	O
antagonist	O
RU	O
486	O
also	O
blocked	O
KV	B-protein
and	O
KCa	B-protein
channels	O
.	O

Progesterone	O
effectively	O
blocked	O
a	O
broad	O
spectrum	O
of	O
K+	B-protein
channels	I-protein
,	O
reducing	O
both	O
Kv1.3	B-protein
and	O
charybdotoxin-resistant	B-protein
components	I-protein
of	O
KV	B-protein
current	O
and	O
KCa	B-protein
current	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
as	O
well	O
as	O
blocking	O
several	O
cloned	B-protein
KV	I-protein
channels	I-protein
expressed	O
in	O
cell	B-cell_line
lines	I-cell_line
.	O

Progesterone	O
had	O
little	O
or	O
no	O
effect	O
on	O
a	O
cloned	B-protein
voltage-gated	I-protein
Na+	I-protein
channel	I-protein
,	O
an	O
inward	O
rectifier	O
K+	B-protein
channel	I-protein
,	O
or	O
on	O
lymphocyte	B-protein
Ca2+	I-protein
and	I-protein
Cl-	I-protein
channels	I-protein
.	O

We	O
propose	O
that	O
direct	O
inhibition	O
of	O
K+	B-protein
channels	I-protein
in	O
T	B-cell_type
cells	I-cell_type
by	O
progesterone	O
contributes	O
to	O
progesterone-induced	O
immunosuppression	O
.	O

A	NULL
Nongenomic	NULL
Mechanism	NULL
for	NULL
Progesterone-mediated	NULL
Imm	NULL
Inhibition	NULL
of	NULL
K+	NULL
Channels	NULL
,	NULL
Ca*®+*	NULL
Signaling	NULL
,	NULL
and	NULL
Gene	NULL
Expression	NULL
in	NULL
T	NULL
Lymphocytes	NULL
By	NULL
George	NULL
R	NULL
.	NULL

Ehring	NULL
,	NULL
Hubert	NULL
H.	NULL
Kerschbaum	NULL
,	NULL
Claudia	NULL
Eder	NULL
,	NULL
Amber	NULL
L.	NULL
Neben	NULL
,	NULL
Christopher	NULL
M.	NULL
Fanger	NULL
,	NULL
R	NULL
osana	NULL
M.	NULL
Khoury	NULL
,	NULL
Paul	NULL
A.	NULL
Negulescu	NULL
,	NULL
and	NULL
Michael	NULL
D.	NULL
Cahalan	NULL
From	NULL
the	NULL
Department	NULL
of	NULL
Physiology	NULL
and	NULL
Biophysics	NULL
University	NULL
of	NULL
Califomia	NULL
,	NULL
Irvine	NULL
Califomia	NULL
92697	NULL
Sum	NULL
m	NULL
ary	NULL
The	NULL
mechanism	NULL
by	NULL
which	NULL
progesterone	NULL
causes	NULL
localized	NULL
suppression	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
during	NULL
pregnancy	NULL
has	NULL
remained	NULL
elusive	NULL
.	NULL

Using	NULL
human	NULL
T	NULL
lymphocytes	NULL
and	NULL
T	NULL
cell	NULL
lines	NULL
,	NULL
we	NULL
show	NULL
that	NULL
progesterone	NULL
,	NULL
at	NULL
concentrations	NULL
found	NULL
in	NULL
the	NULL
placenta	NULL
,	NULL
rapidly	NULL
and	NULL
reversibly	NULL
blocks	NULL
voltage-gated	NULL
and	NULL
calcium-activated	NULL
K*	NULL
channels	NULL
(	NULL
Ky	NULL
and	NULL
K.	NULL
,	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
resulting	NULL
in	NULL
depolarization	NULL
of	NULL
the	NULL
membrane	NULL
potential	NULL
.	NULL

As	NULL
a	NULL
result	NULL
,	NULL
Ca®*	NULL
signaling	NULL
and	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NF-AT	NULL
)	NULL
-driven	NULL
gene	NULL
expression	NULL
are	NULL
inhibited	NULL
.	NULL

Progesterone	NULL
acts	NULL
distally	NULL
to	NULL
the	NULL
initial	NULL
steps	NULL
of	NULL
T	NULL
cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
-mediated	NULL
signal	NULL
transduction	NULL
,	NULL
since	NULL
it	NULL
blocks	NULL
sustained	NULL
Ca®*	NULL
signals	NULL
after	NULL
thapsigargin	NULL
stimulation	NULL
,	NULL
as	NULL
well	NULL
as	NULL
oscillatory	NULL
Ca**	NULL
signals	NULL
,	NULL
but	NULL
not	NULL
the	NULL
Ca®*	NULL
transient	NULL
after	NULL
TCR	NULL
stimulation	NULL
.	NULL

K+	NULL
channel	NULL
blockade	NULL
by	NULL
progesterone	NULL
is	NULL
specific	NULL
;	NULL
other	NULL
steroid	NULL
hormones	NULL
had	NULL
little	NULL
or	NULL
no	NULL
effect	NULL
,	NULL
although	NULL
the	NULL
progesterone	NULL
antagonist	NULL
RU	NULL
486	NULL
also	NULL
blocked	NULL
Ky	NULL
and	NULL
K.	NULL
,	NULL
channels	NULL
.	NULL

Progesterone	NULL
effectively	NULL
blocked	NULL
a	NULL
broad	NULL
spectrum	NULL
of	NULL
K*	NULL
channels	NULL
,	NULL
reducing	NULL
both	NULL
Kv1.3	NULL
and	NULL
charybdotoxin-resistant	NULL
components	NULL
of	NULL
Ky	NULL
current	NULL
and	NULL
Ky	NULL
,	NULL
current	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
as	NULL
well	NULL
as	NULL
blocking	NULL
several	NULL
cloned	NULL
Ky	NULL
channels	NULL
expressed	NULL
in	NULL
cell	NULL
lines	NULL
.	NULL

Progesterone	NULL
had	NULL
little	NULL
or	NULL
no	NULL
effect	NULL
on	NULL
a	NULL
cloned	NULL
voltage-gated	NULL
Na*	NULL
channel	NULL
,	NULL
an	NULL
inward	NULL
rectifier	NULL
K*	NULL
channel	NULL
,	NULL
or	NULL
on	NULL
lymphocyte	NULL
Ca*+*	NULL
and	NULL
CI-	NULL
channels	NULL
.	NULL

We	NULL
propose	NULL
that	NULL
direct	NULL
inhibition	NULL
of	NULL
K+	NULL
channels	NULL
in	NULL
T	NULL
cells	NULL
by	NULL
progesterone	NULL
contributes	NULL
to	NULL
progesterone-	NULL
induced	NULL
immunosuppression	NULL
.	NULL

Key	NULL
words	NULL
:	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
mmunosuppression	NULL
within	NULL
the	NULL
uterus	NULL
is	NULL
crucial	NULL
for	NULL
the	NULL
survival	NULL
of	NULL
the	NULL
fetus	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
maternal	NULL
immune	NULL
system	NULL
becomes	NULL
sensitized	NULL
to	NULL
paternal	NULL
antigens	NULL
during	NULL
pregnancy	NULL
,	NULL
fetal	NULL
cells	NULL
and	NULL
placental	NULL
trophoblasts	NULL
bearing	NULL
those	NULL
antigens	NULL
do	NULL
not	NULL
elicit	NULL
a	NULL
cytolytic	NULL
immune	NULL
response	NULL
(	NULL
3-5	NULL
)	NULL
.	NULL

High	NULL
concentrations	NULL
of	NULL
progesterone	NULL
in	NULL
the	NULL
placenta	NULL
inhibit	NULL
the	NULL
maternal	NULL
immune	NULL
response	NULL
against	NULL
the	NULL
fetal	NULL
al-lograft	NULL
(	NULL
6	NULL
,	NULL
7	NULL
)	NULL
.	NULL

The	NULL
immunosuppressive	NULL
effects	NULL
of	NULL
progesterone	NULL
were	NULL
demonstrated	NULL
in	NULL
vivo	NULL
by	NULL
prolonged	NULL
survival	NULL
of	NULL
xe-nografts	NULL
near	NULL
silastic	NULL
implants	NULL
containing	NULL
progesterone	NULL
at	NULL
concentrations	NULL
typically	NULL
found	NULL
in	NULL
the	NULL
placenta	NULL
(	NULL
3	NULL
,	NULL
6	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
assays	NULL
have	NULL
established	NULL
that	NULL
progesterone	NULL
inhibits	NULL
lymphocyte	NULL
activation	NULL
and	NULL
proliferation	NULL
in	NULL
response	NULL
to	NULL
allogeneic	NULL
cells	NULL
or	NULL
mitogens	NULL
(	NULL
8-10	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
progesterone	NULL
does	NULL
not	NULL
inhibit	NULL
the	NULL
effector	NULL
functions	NULL
of	NULL
previously	NULL
activated	NULL
cytolytic	NULL
T	NULL
cells	NULL
(	NULL
11	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
progesterone	NULL
may	NULL
interfere	NULL
with	NULL
the	NULL
early	NULL
phases	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

G.R	NULL
.	NULL

Ehring	NULL
and	NULL
H.H	NULL
.	NULL

Kerschbaum	NULL
contributed	NULL
equally	NULL
to	NULL
this	NULL
work	NULL
.	NULL

1593	NULL
T	NULL
lymphocyte	NULL
«	NULL
K*	NULL
channel	NULL
*	NULL
calcium	NULL
signaling	NULL
e	NULL
gene	NULL
expression	NULL
*	NULL
nuclear	NULL
factor	NULL
Antigen	NULL
presentation	NULL
and	NULL
TCR	NULL
ligation	NULL
stimulate	NULL
ty-rosine	NULL
kinases	NULL
,	NULL
leading	NULL
to	NULL
the	NULL
generation	NULL
of	NULL
inositol	NULL
1,4,5-trisphosphate	NULL
(	NULL
IP	NULL
;	NULL
)	NULL
'	NULL
and	NULL
a	NULL
consequent	NULL
rise	NULL
in	NULL
the	NULL
cytoplasmic	NULL
calcium	NULL
concentration	NULL
(	NULL
[	NULL
Ca*	NULL
]	NULL
;	NULL
)	NULL
.	NULL

Elevated	NULL
[	NULL
Ca	NULL
``	NULL
+*	NULL
]	NULL
;	NULL
activates	NULL
calcineurin	NULL
,	NULL
a	NULL
phosphatase	NULL
which	NULL
then	NULL
dephosphor-ylates	NULL
a	NULL
cytoplasmic	NULL
transcription	NULL
factor	NULL
,	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NF-AT	NULL
)	NULL
.	NULL

Dephosphorylated	NULL
NF-AT	NULL
moves	NULL
into	NULL
the	NULL
nucleus	NULL
where	NULL
it	NULL
promotes	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
(	NULL
12	NULL
)	NULL
.	NULL

A	NULL
sustained	NULL
elevation	NULL
in	NULL
[	NULL
Ca++	NULL
]	NULL
;	NULL
requiring	NULL
Ca+*	NULL
influx	NULL
across	NULL
the	NULL
plasma	NULL
membrane	NULL
is	NULL
necessary	NULL
for	NULL
the	NULL
retention	NULL
of	NULL
NF-AT	NULL
in	NULL
the	NULL
nucleus	NULL
and	NULL
efficient	NULL
transcription	NULL
of	NULL
IL-2	NULL
(	NULL
13-16	NULL
)	NULL
.	NULL

In	NULL
lymphocytes	NULL
,	NULL
the	NULL
opening	NULL
of	NULL
Ca*	NULL
release-activated	NULL
Ca®+*	NULL
(	NULL
CRAC	NULL
)	NULL
channels	NULL
initiates	NULL
influx	NULL
after	NULL
the	NULL
depletion	NULL
of	NULL
Ca®+*	NULL
stores	NULL
by	NULL
'	NULL
A	NULL
bbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
[	NULL
Ca®*	NULL
}	NULL
;	NULL
,	NULL
intracellular	NULL
free	NULL
calcium	NULL
concen-tration	NULL
;	NULL
CRAC	NULL
,	NULL
Ca	NULL
``	NULL
*	NULL
release-activated	NULL
Ca®*	NULL
;	NULL
CTX	NULL
,	NULL
charybdotoxin	NULL
;	NULL
F	NULL
,	NULL
,	NULL
,	NULL
membrane	NULL
potential	NULL
;	NULL
IP	NULL
;	NULL
,	NULL
inositol	NULL
1,4,5-trisphosphate	NULL
;	NULL
K.	NULL
,	NULL
,	NULL
Ca®*-activated	NULL
K*	NULL
;	NULL
Ky	NULL
,	NULL
voltage-gated	NULL
K*	NULL
;	NULL
NF-AT	NULL
,	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
;	NULL
TG	NULL
,	NULL
thapsigargin	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

©	NULL
The	NULL
R	NULL
ockefeller	NULL
University	NULL
Press	NULL
»	NULL
0022-1007/98/	NULL
11/	NULL
1593/	NULL
10	NULL
$	NULL
2.00	NULL
Volume	NULL
188	NULL
,	NULL
Number	NULL
9	NULL
,	NULL
November	NULL
2	NULL
,	NULL
1998	NULL
1593-1602	NULL
http	NULL
:	NULL
//	NULL
www.jem.org	NULL
IP	NULL
,	NULL
(	NULL
17-19	NULL
)	NULL
.	NULL

Once	NULL
the	NULL
CR	NULL
AC	NULL
channels	NULL
are	NULL
open	NULL
,	NULL
the	NULL
trans	NULL
membrane	NULL
concentration	NULL
gradient	NULL
for	NULL
Ca®+	NULL
and	NULL
the	NULL
membrane	NULL
potential	NULL
(	NULL
F	NULL
,	NULL
,	NULL
)	NULL
provide	NULL
the	NULL
driving	NULL
force	NULL
for	NULL
Ca+	NULL
entry	NULL
.	NULL

E	NULL
,	NULL
,	NULL
,	NULL
is	NULL
set	NULL
by	NULL
the	NULL
interplay	NULL
between	NULL
several	NULL
ion	NULL
channels	NULL
in	NULL
the	NULL
T	NULL
cell	NULL
membrane	NULL
.	NULL

By	NULL
itself	NULL
,	NULL
the	NULL
Ca*®+*	NULL
current	NULL
through	NULL
CRAC	NULL
channels	NULL
would	NULL
diminish	NULL
the	NULL
driving	NULL
force	NULL
for	NULL
calcium	NULL
entry	NULL
by	NULL
reducing	NULL
E	NULL
,	NULL
,	NULL
.	NULL

However	NULL
,	NULL
currents	NULL
through	NULL
voltage-gated	NULL
K*	NULL
(	NULL
Ky	NULL
)	NULL
channels	NULL
and	NULL
Ca+-activated	NULL
K*	NULL
(	NULL
Ke	NULL
,	NULL
)	NULL
channels	NULL
enhance	NULL
Ca+	NULL
entry	NULL
by	NULL
driving	NULL
E	NULL
,	NULL
,	NULL
to	NULL
a	NULL
negative	NULL
voltage	NULL
.	NULL

Chloride	NULL
channels	NULL
may	NULL
also	NULL
play	NULL
a	NULL
role	NULL
in	NULL
maintaining	NULL
a	NULL
negative	NULL
E	NULL
,	NULL
,	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
.	NULL

The	NULL
four	NULL
major	NULL
types	NULL
of	NULL
ion	NULL
channels	NULL
found	NULL
in	NULL
T	NULL
cells	NULL
are	NULL
possible	NULL
targets	NULL
for	NULL
immunosuppressive	NULL
agents	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
the	NULL
Ky	NULL
channel	NULL
encoded	NULL
by	NULL
Kv1.3	NULL
is	NULL
required	NULL
for	NULL
normal	NULL
lymphocyte	NULL
activation	NULL
both	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
(	NULL
14	NULL
,	NULL
22-25	NULL
)	NULL
.	NULL

We	NULL
have	NULL
determined	NULL
the	NULL
effects	NULL
of	NULL
progesterone	NULL
on	NULL
lymphocyte	NULL
ion	NULL
channels	NULL
,	NULL
Ca®*	NULL
signaling	NULL
,	NULL
and	NULL
gene	NULL
expression	NULL
.	NULL

By	NULL
combining	NULL
functional	NULL
assays	NULL
of	NULL
gene	NULL
expression	NULL
with	NULL
patch-clamp	NULL
and	NULL
Ca*®*-imaging	NULL
measurements	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
progesterone	NULL
blocks	NULL
lymphocyte	NULL
K+	NULL
channels	NULL
,	NULL
interferes	NULL
with	NULL
TCR	NULL
-induced	NULL
[	NULL
Ca	NULL
``	NULL
+	NULL
]	NULL
;	NULL
signaling	NULL
,	NULL
and	NULL
inhibits	NULL
gene	NULL
expression	NULL
.	NULL

We	NULL
propose	NULL
that	NULL
progesterone	NULL
acts	NULL
as	NULL
an	NULL
endogenous	NULL
immunosuppressant	NULL
by	NULL
directly	NULL
and	NULL
revers	NULL
ibly	NULL
blocking	NULL
K*	NULL
channels	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Chemiails	NULL
and	NULL
Solutions	NULL
.	NULL

Salts	NULL
and	NULL
other	NULL
reagents	NULL
were	NULL
obtained	NULL
from	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
(	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
unless	NULL
otherwise	NULL
noted	NULL
.	NULL

Thapsigargin	NULL
(	NULL
TG	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
Alexis	NULL
Corp.	NULL
(	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Progesterone	NULL
(	NULL
10	NULL
mM	NULL
)	NULL
and	NULL
PMA	NULL
(	NULL
3	NULL
mM	NULL
)	NULL
stocks	NULL
were	NULL
prepared	NULL
in	NULL
DMSO	NULL
.	NULL

Cell	NULL
Culture	NULL
-	NULL
B3Z	NULL
cells	NULL
and	NULL
K897	NULL
cells	NULL
were	NULL
provided	NULL
along	NULL
with	NULL
the	NULL
antigenic	NULL
peptide	NULL
fragment	NULL
SIINFEKL	NULL
by	NULL
Dr.	NULL
N.	NULL
Shastri	NULL
(	NULL
University	NULL
of	NULL
California	NULL
,	NULL
Berkeley	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

B3Z	NULL
cells	NULL
are	NULL
a	NULL
murine	NULL
,	NULL
CD8*	NULL
,	NULL
T	NULL
cell	NULL
hybridoma	NULL
with	NULL
a	NULL
known	NULL
antigen	NULL
specificity	NULL
for	NULL
OVA/K°-MHC	NULL
and	NULL
containing	NULL
a	NULL
-galactosidase	NULL
reporter	NULL
gene	NULL
construct	NULL
(	NULL
aZ	NULL
)	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
NF-AT	NULL
promoter	NULL
(	NULL
26	NULL
)	NULL
.	NULL

The	NULL
corresponding	NULL
antigen-presenting	NULL
K897	NULL
cells	NULL
had	NULL
been	NULL
trans	NULL
fected	NULL
with	NULL
K®	NULL
class	NULL
I	NULL
MHC	NULL
as	NULL
described	NULL
(	NULL
27	NULL
)	NULL
.	NULL

The	NULL
human	NULL
leukemia	NULL
T	NULL
cell	NULL
line	NULL
Jurkat	NULL
E6-1	NULL
was	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

Human	NULL
peripheral	NULL
T	NULL
lymphocytes	NULL
were	NULL
collected	NULL
from	NULL
venous	NULL
blood	NULL
of	NULL
healthy	NULL
volunteers	NULL
and	NULL
isolated	NULL
using	NULL
a	NULL
Ficoll-Hypaque	NULL
density	NULL
gradient	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
28	NULL
)	NULL
.	NULL

A	NULL
population	NULL
of	NULL
activated	NULL
T	NULL
cell	NULL
blasts	NULL
was	NULL
prepared	NULL
in	NULL
culture	NULL
by	NULL
treating	NULL
the	NULL
resting	NULL
cells	NULL
with	NULL
10	NULL
pg/ml	NULL
PHA	NULL
(	NULL
PHA-P	NULL
;	NULL
Difco	NULL
Laboratories	NULL
,	NULL
Inc.	NULL
,	NULL
Detroit	NULL
,	NULL
MI	NULL
)	NULL
.	NULL

Cell	NULL
lines	NULL
expressing	NULL
the	NULL
cloned	NULL
Ky	NULL
channels	NULL
Kv1.1	NULL
,	NULL
Kv1.2	NULL
,	NULL
Kv1.3	NULL
,	NULL
Kvl1.4	NULL
,	NULL
Kv1.5	NULL
,	NULL
and	NULL
Kv3.1	NULL
and	NULL
a	NULL
voltage-gated	NULL
Na*	NULL
channel	NULL
hSKM1	NULL
were	NULL
maintained	NULL
in	NULL
culture	NULL
.	NULL

All	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
,	NULL
10	NULL
mM	NULL
Hepes	NULL
,	NULL
2	NULL
mM	NULL
glutamine	NULL
,	NULL
1	NULL
mM	NULL
pyruvate	NULL
,	NULL
50	NULL
M	NULL
2-ME	NULL
.	NULL

Cells	NULL
were	NULL
cultured	NULL
in	NULL
25-ml	NULL
flasks	NULL
(	NULL
Costar	NULL
Corp.	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
at	NULL
37°C	NULL
,	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
in	NULL
a	NULL
humidified	NULL
incubator	NULL
.	NULL

For	NULL
experiments	NULL
on	NULL
inward	NULL
rectifier	NULL
K+	NULL
channels	NULL
,	NULL
rat	NULL
basophilic	NULL
leukemia	NULL
(	NULL
RBL	NULL
)	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
Eagle	NULL
's	NULL
MEM	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
and	NULL
1	NULL
%	NULL
1-glutamine	NULL
.	NULL

R	NULL
BL	NULL
cells	NULL
were	NULL
plated	NULL
onto	NULL
glass	NULL
coverslips	NULL
1-2	NULL
d	NULL
before	NULL
use	NULL
.	NULL

LacZ	NULL
,	NULL
Reporter	NULL
Gene	NULL
Assay	NULL
.	NULL

The	NULL
fraction	NULL
of	NULL
B3Z	NULL
cells	NULL
expressing	NULL
B-galactosidase	NULL
was	NULL
measured	NULL
using	NULL
flow	NULL
cytometry	NULL
(	NULL
FAC-	NULL
1594	NULL
Scan®	NULL
;	NULL
Becton	NULL
Dickinson	NULL
,	NULL
San	NULL
Jose	NULL
,	NULL
CA	NULL
)	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
13	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
5	NULL
X	NULL
104	NULL
cells	NULL
in	NULL
RPMI	NULL
without	NULL
serum	NULL
were	NULL
placed	NULL
in	NULL
individual	NULL
wells	NULL
of	NULL
24-	NULL
well	NULL
plates	NULL
activated	NULL
either	NULL
by	NULL
1	NULL
wM	NULL
TG	NULL
plus	NULL
50	NULL
nM	NULL
PMA	NULL
or	NULL
by	NULL
antibodies	NULL
to	NULL
the	NULL
CD3-e	NULL
subunit	NULL
of	NULL
the	NULL
TCR	NULL
complex	NULL
.	NULL

In	NULL
the	NULL
latter	NULL
,	NULL
wells	NULL
were	NULL
coated	NULL
with	NULL
10	NULL
g/ml	NULL
anti-CD3-e	NULL
antibodies	NULL
(	NULL
PharMingen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
overnight	NULL
and	NULL
rinsed	NULL
briefly	NULL
with	NULL
PBS	NULL
before	NULL
use	NULL
.	NULL

Cells	NULL
were	NULL
activated	NULL
in	NULL
the	NULL
incubator	NULL
for	NULL
a	NULL
total	NULL
of	NULL
4	NULL
h	NULL
before	NULL
being	NULL
resuspended	NULL
and	NULL
loaded	NULL
by	NULL
osmotic	NULL
shock	NULL
with	NULL
the	NULL
fluorogenic	NULL
substrate	NULL
,	NULL
fluores	NULL
cein-di-B-galactopyranoside	NULL
(	NULL
FDG	NULL
;	NULL
Molecular	NULL
Probes	NULL
,	NULL
Inc.	NULL
,	NULL
Eu-gene	NULL
,	NULL
OR	NULL
)	NULL
.	NULL

The	NULL
fluorescence	NULL
of	NULL
laZ	NULL
#	NULL
Z*	NULL
cells	NULL
was	NULL
at	NULL
least	NULL
fivefold	NULL
greater	NULL
than	NULL
autofluorescence	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
progesterone	NULL
on	NULL
lakZ	NULL
gene	NULL
expression	NULL
was	NULL
quantified	NULL
using	NULL
a	NULL
MUG	NULL
(	NULL
4-methylumbel-liferyl	NULL
B-d-galactopyranoside	NULL
)	NULL
assay	NULL
(	NULL
29	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
B3Z	NULL
cells	NULL
were	NULL
plated	NULL
at	NULL
10°	NULL
cells	NULL
per	NULL
well	NULL
in	NULL
96-well	NULL
plates	NULL
,	NULL
and	NULL
the	NULL
fluorescence	NULL
produced	NULL
by	NULL
cell	NULL
lysates	NULL
in	NULL
a	NULL
solution	NULL
containing	NULL
3	NULL
mM	NULL
MUG	NULL
was	NULL
measured	NULL
in	NULL
a	NULL
multi-well	NULL
plate	NULL
reader	NULL
(	NULL
CytoFluor	NULL
Series	NULL
4000	NULL
;	NULL
PerSeptive	NULL
Biosystems	NULL
,	NULL
Framingham	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Patch-damp	NULL
Recordings	NULL
.	NULL

Membrane	NULL
currents	NULL
were	NULL
measured	NULL
using	NULL
the	NULL
whole-cell	NULL
configuration	NULL
of	NULL
the	NULL
patch-clamp	NULL
technique	NULL
(	NULL
28	NULL
,	NULL
30	NULL
)	NULL
,	NULL
and	NULL
membrane	NULL
potential	NULL
was	NULL
measured	NULL
using	NULL
the	NULL
perforated	NULL
patch	NULL
method	NULL
in	NULL
current-clamp	NULL
mode	NULL
with	NULL
nystatin	NULL
to	NULL
per-meabilize	NULL
the	NULL
cells	NULL
(	NULL
31	NULL
)	NULL
.	NULL

An	NULL
EPC-9	NULL
amplifier	NULL
(	NULL
HEKA	NULL
,	NULL
Lambrecht/	NULL
Pfalz	NULL
,	NULL
Germany	NULL
)	NULL
interfaced	NULL
to	NULL
a	NULL
Macintosh	NULL
Quadra	NULL
700	NULL
computer	NULL
was	NULL
used	NULL
for	NULL
pulse	NULL
application	NULL
and	NULL
data	NULL
recording	NULL
.	NULL

Membrane	NULL
voltages	NULL
were	NULL
corrected	NULL
for	NULL
liquid	NULL
junction	NULL
potentials	NULL
,	NULL
and	NULL
current	NULL
recordings	NULL
were	NULL
corrected	NULL
for	NULL
leak	NULL
and	NULL
capacitative	NULL
currents	NULL
.	NULL

Patch	NULL
pipettes	NULL
were	NULL
pulled	NULL
from	NULL
Accu-fill	NULL
90	NULL
Micropets	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
Parsippany	NULL
,	NULL
NJ	NULL
)	NULL
using	NULL
a	NULL
P87	NULL
micropipette	NULL
puller	NULL
(	NULL
Sut-ter	NULL
Instruments	NULL
Co.	NULL
,	NULL
Novato	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Pipettes	NULL
were	NULL
coated	NULL
with	NULL
Sylgard	NULL
(	NULL
Dow	NULL
Corning	NULL
Corp.	NULL
,	NULL
Midland	NULL
,	NULL
MI	NULL
)	NULL
and	NULL
heat	NULL
polished	NULL
to	NULL
final	NULL
resistances	NULL
of	NULL
2-5	NULL
MOQ	NULL
.	NULL

Patch-clamp	NULL
experiments	NULL
were	NULL
performed	NULL
at	NULL
room	NULL
temperature	NULL
(	NULL
20-25°C	NULL
)	NULL
.	NULL

Unless	NULL
otherwise	NULL
in-dicated	NULL
,	NULL
the	NULL
membrane	NULL
currents	NULL
were	NULL
filtered	NULL
at	NULL
1.5	NULL
kHz	NULL
.	NULL

Data	NULL
analysis	NULL
was	NULL
performed	NULL
using	NULL
the	NULL
program	NULL
Pulse	NULL
(	NULL
HEKA	NULL
)	NULL
.	NULL

Mammalian	NULL
Ringer	NULL
contained	NULL
(	NULL
in	NULL
mM	NULL
)	NULL
:	NULL
160	NULL
NaCI	NULL
,	NULL
4.5	NULL
KCI	NULL
,	NULL
2	NULL
CaC	NULL
]	NULL
;	NULL
,	NULL
1	NULL
MgC	NULL
)	NULL
,	NULL
10	NULL
Hepes	NULL
(	NULL
pH	NULL
7.4	NULL
;	NULL
osmolality	NULL
290-310	NULL
mosmol/	NULL
kg	NULL
)	NULL
.	NULL

The	NULL
ionic	NULL
composition	NULL
of	NULL
the	NULL
pipette	NULL
solutions	NULL
used	NULL
in	NULL
the	NULL
individual	NULL
experiments	NULL
is	NULL
reported	NULL
in	NULL
the	NULL
figure	NULL
legends	NULL
.	NULL

[	NULL
C	NULL
@	NULL
*	NULL
]	NULL
,	NULL
Measurement	NULL
.	NULL

[	NULL
C	NULL
#	NULL
*	NULL
]	NULL
,	NULL
was	NULL
measured	NULL
ratiometrically	NULL
using	NULL
fura-2	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
13	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
cells	NULL
were	NULL
loaded	NULL
with	NULL
3	NULL
M	NULL
fura-2/	NULL
AM	NULL
(	NULL
Molecular	NULL
Probes	NULL
,	NULL
Inc.	NULL
)	NULL
for	NULL
30-40	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
(	NULL
20-25°C	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
RPMI/	NULL
10	NULL
%	NULL
FCS	NULL
and	NULL
stored	NULL
in	NULL
the	NULL
dark	NULL
.	NULL

IMlumi-nation	NULL
was	NULL
provided	NULL
by	NULL
a	NULL
xenon	NULL
arc-lamp	NULL
(	NULL
Carl	NULL
Zeiss	NULL
,	NULL
Jena	NULL
,	NULL
Germany	NULL
)	NULL
and	NULL
transmitted	NULL
through	NULL
a	NULL
filter	NULL
wheel	NULL
unit	NULL
(	NULL
Lambda	NULL
10	NULL
;	NULL
Axon	NULL
Instruments	NULL
,	NULL
Inc.	NULL
,	NULL
Foster	NULL
City	NULL
,	NULL
CA	NULL
)	NULL
containing	NULL
350-	NULL
and	NULL
385-nm	NULL
excitation	NULL
filters	NULL
.	NULL

The	NULL
filtered	NULL
light	NULL
was	NULL
reflected	NULL
by	NULL
a	NULL
400-nm	NULL
dichroic	NULL
mirror	NULL
through	NULL
a	NULL
63	NULL
%	NULL
oil-immersion	NULL
objective	NULL
to	NULL
illuminate	NULL
cells	NULL
.	NULL

Emitted	NULL
light	NULL
>	NULL
480	NULL
nm	NULL
was	NULL
received	NULL
by	NULL
a	NULL
SIT	NULL
camera	NULL
(	NULL
C2400	NULL
;	NULL
Hamamatsu	NULL
Photonics	NULL
,	NULL
Bridgewater	NULL
,	NULL
NJ	NULL
)	NULL
and	NULL
the	NULL
video	NULL
information	NULL
relayed	NULL
to	NULL
an	NULL
image	NULL
processing	NULL
system	NULL
(	NULL
Videoprobe	NULL
;	NULL
ETM	NULL
Systems	NULL
,	NULL
Petaluma	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Full	NULL
field-of-view	NULL
8-bit	NULL
images	NULL
,	NULL
averaged	NULL
over	NULL
16	NULL
frames	NULL
,	NULL
were	NULL
collected	NULL
at	NULL
350-	NULL
and	NULL
385-nm	NULL
wavelengths	NULL
.	NULL

Digitally	NULL
stored	NULL
350/385	NULL
ratios	NULL
were	NULL
constructed	NULL
from	NULL
background-corrected	NULL
350-	NULL
and	NULL
385-nm	NULL
images	NULL
.	NULL

Single-cell	NULL
measurements	NULL
of	NULL
[	NULL
Ca*	NULL
]	NULL
;	NULL
were	NULL
calculated	NULL
from	NULL
the	NULL
350/385	NULL
ratios	NULL
using	NULL
the	NULL
equation	NULL
of	NULL
Grynkiewicz	NULL
et	NULL
al	NULL
.	NULL

(	NULL
32	NULL
)	NULL
and	NULL
a	NULL
K	NULL
,	NULL
of	NULL
250	NULL
nM	NULL
for	NULL
fura2	NULL
.	NULL

The	NULL
minimum	NULL
350/385	NULL
ratio	NULL
was	NULL
measured	NULL
in	NULL
single	NULL
cells	NULL
after	NULL
incubation	NULL
for	NULL
10	NULL
min	NULL
in	NULL
Ca®*-free	NULL
Ringer	NULL
containing	NULL
2	NULL
mM	NULL
EGTA	NULL
.	NULL

Maximum	NULL
ratio	NULL
values	NULL
were	NULL
obtained	NULL
after	NULL
perfusion	NULL
with	NULL
R	NULL
inger	NULL
containing	NULL
10	NULL
mM	NULL
Ca®+	NULL
,	NULL
1	NULL
pM	NULL
TG	NULL
,	NULL
and	NULL
10	NULL
M	NULL
ionomycin	NULL
.	NULL

Progesterone	NULL
Blocks	NULL
K*	NULL
Channels	NULL
and	NULL
T	NULL
Cell	NULL
Activation	NULL
Data	NULL
Analysis	NULL
.	NULL

-	NULL
Numerical	NULL
values	NULL
for	NULL
single-cell	NULL
[	NULL
Ca®*	NULL
]	NULL
;	NULL
traces	NULL
were	NULL
analyzed	NULL
with	NULL
Origin	NULL
(	NULL
Microcal	NULL
Software	NULL
,	NULL
Inc.	NULL
,	NULL
Northamp-ton	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Statistical	NULL
analysis	NULL
was	NULL
performed	NULL
on	NULL
data	NULL
sets	NULL
using	NULL
Excel	NULL
version	NULL
5.0	NULL
(	NULL
Microsoft	NULL
Corp.	NULL
,	NULL
Redmond	NULL
,	NULL
WA	NULL
)	NULL
.	NULL

Data	NULL
are	NULL
reported	NULL
as	NULL
mean	NULL
*	NULL
SD	NULL
.	NULL

Analysis	NULL
of	NULL
variance	NULL
(	NULL
ANOVA	NULL
)	NULL
or	NULL
Student	NULL
's	NULL
rf	NULL
test	NULL
was	NULL
used	NULL
to	NULL
compare	NULL
mean	NULL
values	NULL
.	NULL

Pairs	NULL
of	NULL
means	NULL
were	NULL
considered	NULL
statistically	NULL
different	NULL
if	NULL
P	NULL
<	NULL
0.05	NULL
.	NULL

Results	NULL
Progesterone	NULL
Suppresses	NULL
Gene	NULL
Expression	NULL
Driven	NULL
by	NULL
NF-AT	NULL
.	NULL

The	NULL
murine	NULL
T	NULL
cell	NULL
hybridoma	NULL
,	NULL
B3Z	NULL
,	NULL
recognizes	NULL
an	NULL
oc-tapeptide	NULL
fragment	NULL
from	NULL
ovalbumin	NULL
(	NULL
SIINFEKL	NULL
)	NULL
and	NULL
expresses	NULL
the	NULL
lacZ	NULL
reporter	NULL
construct	NULL
under	NULL
transcriptional	NULL
control	NULL
of	NULL
the	NULL
NF-AT	NULL
response	NULL
element	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
26	NULL
,	NULL
27	NULL
)	NULL
.	NULL

Several	NULL
treatments	NULL
that	NULL
increase	NULL
[	NULL
Ca®+	NULL
]	NULL
;	NULL
lead	NULL
to	NULL
NF-AT-driven	NULL
la	NULL
expression	NULL
in	NULL
B3Z	NULL
cells	NULL
(	NULL
13	NULL
)	NULL
,	NULL
including	NULL
TCR	NULL
engagement	NULL
or	NULL
stimulation	NULL
with	NULL
TG	NULL
,	NULL
a	NULL
specific	NULL
inhibitor	NULL
of	NULL
the	NULL
endoplasmic	NULL
reticulum	NULL
C	NULL
#	NULL
+-ATPase	NULL
(	NULL
33	NULL
)	NULL
.	NULL

By	NULL
flow	NULL
cytometry	NULL
in	NULL
the	NULL
present	NULL
series	NULL
of	NULL
ex-periments	NULL
,	NULL
cross-linking	NULL
the	NULL
TCR	NULL
with	NULL
anti-CD3-€e	NULL
antibodies	NULL
or	NULL
stimulating	NULL
with	NULL
TG	NULL
plus	NULL
PMA	NULL
produced	NULL
lak	NULL
expression	NULL
in	NULL
the	NULL
majority	NULL
of	NULL
B3Z	NULL
cells	NULL
(	NULL
60	NULL
+	NULL
4	NULL
%	NULL
,	NULL
n	NULL
=	NULL
7	NULL
;	NULL
or	NULL
72	NULL
+	NULL
10	NULL
%	NULL
,	NULL
n	NULL
=	NULL
3	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

Progesterone	NULL
reduced	NULL
NF-AT-mediated	NULL
laZ	NULL
gene	NULL
expression	NULL
in	NULL
a	NULL
concentration-dependent	NULL
manner	NULL
,	NULL
with	NULL
an	NULL
IC	NULL
;	NULL
,	NULL
value	NULL
of	NULL
22	NULL
+	NULL
2.1	NULL
pM	NULL
in	NULL
cells	NULL
stimulated	NULL
by	NULL
TG/PMA	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
A	NULL
,	NULL
filled	NULL
ardes	NULL
)	NULL
.	NULL

The	NULL
progesterone	NULL
antagonist	NULL
RU	NULL
486	NULL
also	NULL
inhibited	NULL
gene	NULL
expression	NULL
with	NULL
slightly	NULL
lower	NULL
potency	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
A	NULL
,	NULL
open	NULL
squares	NULL
)	NULL
.	NULL

Progesterone	NULL
reduced	NULL
laZ	NULL
expression	NULL
when	NULL
B3Z	NULL
cells	NULL
were	NULL
stimulated	NULL
by	NULL
TG	NULL
alone	NULL
or	NULL
with	NULL
PMA	NULL
,	NULL
by	NULL
immobilized	NULL
anti-CD3-e	NULL
antibody	NULL
,	NULL
or	NULL
by	NULL
antigen	NULL
presentation	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
B	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
at	NULL
concentrations	NULL
normally	NULL
obtained	NULL
in	NULL
the	NULL
placenta	NULL
(	NULL
34	NULL
,	NULL
35	NULL
)	NULL
,	NULL
progesterone	NULL
inhibits	NULL
NF-AT-mediated	NULL
gene	NULL
expression	NULL
when	NULL
driven	NULL
by	NULL
four	NULL
treatments	NULL
that	NULL
increase	NULL
[	NULL
Ca+	NULL
]	NULL
;	NULL
.	NULL

Our	NULL
results	NULL
with	NULL
NF-AT-driven	NULL
lak	NULL
re	NULL
porter	NULL
gene	NULL
expression	NULL
are	NULL
consistent	NULL
with	NULL
levels	NULL
of	NULL
progesterone	NULL
or	NULL
RU	NULL
486	NULL
shown	NULL
previously	NULL
to	NULL
inhibit	NULL
activation	NULL
of	NULL
human	NULL
T	NULL
cells	NULL
in	NULL
vitro	NULL
(	NULL
8	NULL
,	NULL
9	NULL
)	NULL
.	NULL

Progesterone	NULL
Inhibits	NULL
[	NULL
C*	NULL
]	NULL
,	NULL
Signals	NULL
in	NULL
T	NULL
Cells	NULL
after	NULL
TCR	NULL
Engagement	NULL
or	NULL
TG	NULL
Stimulation	NULL
.	NULL

-	NULL
Upon	NULL
contact	NULL
with	NULL
K897	NULL
cells	NULL
preloaded	NULL
with	NULL
SIINFEKL	NULL
,	NULL
B3Z	NULL
cells	NULL
responded	NULL
with	NULL
an	NULL
initial	NULL
Ca®+*	NULL
transient	NULL
from	NULL
a	NULL
resting	NULL
[	NULL
Ca	NULL
``	NULL
+	NULL
]	NULL
;	NULL
of	NULL
180	NULL
+	NULL
86	NULL
nM	NULL
to	NULL
a	NULL
peak	NULL
of	NULL
2.5	NULL
+	NULL
0.5	NULL
M	NULL
(	NULL
n	NULL
=	NULL
20	NULL
)	NULL
,	NULL
followed	NULL
by	NULL
sustained	NULL
Ca	NULL
``	NULL
+	NULL
oscillations	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
A	NULL
)	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
preloaded	NULL
anti-gen	NULL
,	NULL
K897	NULL
cells	NULL
did	NULL
not	NULL
elicit	NULL
Ca+*	NULL
signaling	NULL
in	NULL
B3Z	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Application	NULL
of	NULL
50	NULL
M	NULL
progesterone	NULL
reversibly	NULL
suppressed	NULL
antigen-induced	NULL
Ca+	NULL
oscillations	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
A	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
progesterone	NULL
directly	NULL
inhibits	NULL
TCR	NULL
-ini-tiated	NULL
signaling	NULL
or	NULL
interferes	NULL
with	NULL
costimulatory	NULL
pathways	NULL
,	NULL
we	NULL
activated	NULL
the	NULL
TCR	NULL
complex	NULL
by	NULL
cross-linking	NULL
CD3	NULL
.	NULL

Settling	NULL
B3Z	NULL
cells	NULL
onto	NULL
chambers	NULL
coated	NULL
with	NULL
anti-CD3-e	NULL
antibodies	NULL
elicited	NULL
an	NULL
initial	NULL
Ca®*	NULL
transient	NULL
followed	NULL
by	NULL
vigorous	NULL
oscillations	NULL
that	NULL
continued	NULL
for	NULL
at	NULL
least	NULL
40	NULL
min	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
B	NULL
)	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
50	NULL
jyM	NULL
progesterone	NULL
,	NULL
most	NULL
cells	NULL
produced	NULL
only	NULL
the	NULL
initial	NULL
Ca®*	NULL
transient	NULL
lasting	NULL
271	NULL
*	NULL
178	NULL
s	NULL
,	NULL
or	NULL
a	NULL
transient	NULL
followed	NULL
by	NULL
severely	NULL
attenuated	NULL
oscillations	NULL
(	NULL
r	NULL
=	NULL
14	NULL
;	NULL
Fig	NULL
.	NULL

2	NULL
C	NULL
)	NULL
.	NULL

These	NULL
data	NULL
demonstrate	NULL
that	NULL
progesterone	NULL
blocks	NULL
C+	NULL
signaling	NULL
after	NULL
TCR	NULL
engage-ment	NULL
.	NULL

Since	NULL
the	NULL
initial	NULL
Ca+	NULL
transient	NULL
results	NULL
from	NULL
IP	NULL
;	NULL
-mediated	NULL
release	NULL
of	NULL
from	NULL
intracellular	NULL
stores	NULL
,	NULL
and	NULL
the	NULL
sustained	NULL
Ca*+*	NULL
signal	NULL
requires	NULL
Ca®*	NULL
influx	NULL
,	NULL
these	NULL
data	NULL
also	NULL
suggest	NULL
that	NULL
progesterone	NULL
inhibits	NULL
Ca+*	NULL
influx	NULL
but	NULL
not	NULL
the	NULL
steps	NULL
that	NULL
lead	NULL
to	NULL
Ca*+*	NULL
release	NULL
from	NULL
intracellular	NULL
stores	NULL
.	NULL

TG	NULL
inhibits	NULL
the	NULL
Ca*®+*	NULL
reuptake	NULL
pump	NULL
,	NULL
leading	NULL
to	NULL
depletion	NULL
of	NULL
the	NULL
intracellular	NULL
Ca+*	NULL
stores	NULL
and	NULL
Ca*+*	NULL
influx	NULL
while	NULL
bypassing	NULL
the	NULL
initial	NULL
steps	NULL
of	NULL
TCR	NULL
signaling	NULL
and	NULL
IP	NULL
;	NULL
generation	NULL
(	NULL
36	NULL
,	NULL
37	NULL
)	NULL
.	NULL

In	NULL
resting	NULL
human	NULL
T	NULL
cells	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
TG	NULL
to	NULL
the	NULL
bathing	NULL
solution	NULL
increased	NULL
[	NULL
Ca®+	NULL
]	NULL
;	NULL
from	NULL
72	NULL
+	NULL
8	NULL
nM	NULL
to	NULL
a	NULL
stable	NULL
plateau	NULL
level	NULL
of	NULL
1.2	NULL
+	NULL
0.1	NULL
wM	NULL
(	NULL
n	NULL
=	NULL
76	NULL
;	NULL
Fig	NULL
.	NULL

3	NULL
A	NULL
)	NULL
.	NULL

Progesterone	NULL
reversibly	NULL
inhibited	NULL
the	NULL
sustained	NULL
C+	NULL
signal	NULL
with	NULL
an	NULL
ICs	NULL
,	NULL
value	NULL
of	NULL
28	NULL
+	NULL
2.7	NULL
pM	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
A	NULL
and	NULL
Figure	NULL
1	NULL
.	NULL

Progesterone	NULL
inhibits	NULL
NF-AT-mediated	NULL
gene	NULL
expression	NULL
in	NULL
B3Z	NULL
cells	NULL
(	NULL
4	NULL
)	NULL
The	NULL
concentration-dependent	NULL
inhibition	NULL
of	NULL
laZ	NULL
,	NULL
.	NULL

expression	NULL
in	NULL
B3Z	NULL
cells	NULL
by	NULL
progesterone	NULL
(	NULL
@	NULL
)	NULL
or	NULL
RU	NULL
486	NULL
(	NULL
C	NULL
)	NULL
was	NULL
measured	NULL
in	NULL
a	NULL
multiwell	NULL
fluorescence	NULL
plate	NULL
reader	NULL
using	NULL
MUG	NULL
as	NULL
a	NULL
substrate	NULL
for	NULL
B-galactosidase	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
4	NULL
h	NULL
with	NULL
1	NULL
wM	NULL
TG	NULL
plus	NULL
50	NULL
nM	NULL
PMA	NULL
.	NULL

For	NULL
each	NULL
experiment	NULL
,	NULL
triplicate	NULL
samples	NULL
were	NULL
corrected	NULL
for	NULL
background	NULL
fluorescence	NULL
and	NULL
normalized	NULL
for	NULL
control	NULL
laZ	NULL
expression	NULL
.	NULL

B	NULL
A	NULL
18000	NULL
é	NULL
1.07	NULL
®	NULL
-	NULL
Progesterone	NULL
$	NULL
e	NULL
o	NULL
Russe	NULL
3	NULL
fel	NULL
0.87	NULL
C	NULL
é	NULL
F	NULL
a	NULL
&	NULL
12000	NULL
8	NULL
p	NULL
s	NULL
£	NULL
-	NULL
@	NULL
§	NULL
-	NULL
oa	NULL
!	NULL

§	NULL
5	NULL
$	NULL
-	NULL
sono	NULL
5	NULL
©	NULL
a	NULL
0.24	NULL
o	NULL
s	NULL
&	NULL
fos	NULL
0.04	NULL
04	NULL
0	NULL
.	NULL

1	NULL
10	NULL
100	NULL
[	NULL
Steroid	NULL
]	NULL
(	NULL
uM	NULL
)	NULL
TG	NULL
TG	NULL
+	NULL
PMA	NULL
-	NULL
«	NULL
CD3	NULL
Data	NULL
are	NULL
presented	NULL
as	NULL
mean	NULL
*	NULL
SD	NULL
(	NULL
n	NULL
=	NULL
10	NULL
)	NULL
,	NULL
and	NULL
were	NULL
fitted	NULL
to	NULL
a	NULL
Hill	NULL
equation	NULL
of	NULL
the	NULL
form	NULL
ymax	NULL
szg	NULL
,	NULL
where	NULL
y	NULL
=	NULL
the	NULL
fraction	NULL
of	NULL
control	NULL
laZ	NULL
expression	NULL
with	NULL
a	NULL
maximum	NULL
level	NULL
represented	NULL
by	NULL
y	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
[	NULL
X	NULL
]	NULL
=	NULL
the	NULL
concentration	NULL
of	NULL
progesterone	NULL
,	NULL
ICs	NULL
,	NULL
=	NULL
the	NULL
dissociation	NULL
constant	NULL
,	NULL
and	NULL
n	NULL
=	NULL
the	NULL
Hill	NULL
coefficient	NULL
.	NULL

The	NULL
curve	NULL
represents	NULL
a	NULL
Hill	NULL
equation	NULL
with	NULL
an	NULL
ICs	NULL
,	NULL
value	NULL
of	NULL
22	NULL
+	NULL
2.1	NULL
uM	NULL
and	NULL
n	NULL
=	NULL
1.7	NULL
+	NULL
0.3	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
progesterone	NULL
were	NULL
not	NULL
due	NULL
to	NULL
nonspecific	NULL
toxicity	NULL
,	NULL
since	NULL
after	NULL
treatment	NULL
with	NULL
30	NULL
pM	NULL
progesterone	NULL
,	NULL
>	NULL
95	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
stained	NULL
with	NULL
vital	NULL
stain	NULL
acetoxy-meth-oxy	NULL
calcein	NULL
and	NULL
<	NULL
5	NULL
%	NULL
stained	NULL
with	NULL
propidium	NULL
iodide	NULL
,	NULL
a	NULL
dye	NULL
that	NULL
is	NULL
excluded	NULL
from	NULL
live	NULL
cells	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Application	NULL
of	NULL
30	NULL
M	NULL
progesterone	NULL
reduced	NULL
la	NULL
expression	NULL
when	NULL
B3Z	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
4	NULL
h	NULL
by	NULL
1	NULL
M	NULL
TG	NULL
alone	NULL
,	NULL
a	NULL
combination	NULL
of	NULL
1	NULL
wM	NULL
TG	NULL
plus	NULL
50	NULL
nM	NULL
PMA	NULL
(	NULL
TG	NULL
+	NULL
PMA	NULL
)	NULL
,	NULL
immobilized	NULL
anti-CD3-e	NULL
anti-bodies	NULL
,	NULL
or	NULL
K897	NULL
cells	NULL
presenting	NULL
SIINFEKL	NULL
.	NULL

Fluorescence	NULL
readouts	NULL
from	NULL
the	NULL
multiwell	NULL
plate	NULL
reader	NULL
in	NULL
arbitrary	NULL
units	NULL
(	NULL
a	NULL
u	NULL
.	NULL
)	NULL

are	NULL
presented	NULL
as	NULL
mean	NULL
+	NULL
SD	NULL
(	NULL
white	NULL
bars	NULL
,	NULL
stimulation	NULL
alone	NULL
;	NULL
hatched	NULL
burs	NULL
,	NULL
stimulation	NULL
plus	NULL
30	NULL
M	NULL
progesterone	NULL
)	NULL
.	NULL

*Significance	NULL
was	NULL
determined	NULL
with	NULL
one-tail	NULL
7	NULL
tests	NULL
(	NULL
P	NULL
<	NULL
0.0001	NULL
)	NULL
.	NULL

1595	NULL
_	NULL
Ehring	NULL
et	NULL
al	NULL
.	NULL

A	NULL
&	NULL
B	NULL
a	NULL
b	NULL
wod	NULL
wl	NULL
5	NULL
uch	NULL
5	NULL
|	NULL
Mims	NULL
$	NULL
3	NULL
0	NULL
.0	NULL
da	NULL
WH'MM	NULL
SS	NULL
.	NULL

g	NULL
a	NULL
.o	NULL
J	NULL
‘	NULL
MMM	NULL
Wiha	NULL
.	NULL

kw	NULL
Douitiaa	NULL
-	NULL
_-_	NULL
1000	NULL
s	NULL
MUM	NULL
Muds	NULL
A	NULL
.	NULL

“	NULL
Mm	NULL
1000	NULL
s	NULL
1000	NULL
s	NULL
Figure	NULL
2	NULL
.	NULL

-	NULL
Progesterone	NULL
inhibits	NULL
oscillations	NULL
induced	NULL
by	NULL
TCR	NULL
li-gation	NULL
.	NULL

(	NULL
A	NULL
)	NULL
[	NULL
Ca	NULL
?	NULL

+*	NULL
]	NULL
;	NULL
responses	NULL
from	NULL
four	NULL
representative	NULL
B3Z	NULL
cells	NULL
activated	NULL
by	NULL
contact	NULL
with	NULL
SIINFEKL-presenting	NULL
K897	NULL
cells	NULL
illustrate	NULL
that	NULL
[	NULL
C	NULL
#	NULL
*	NULL
]	NULL
,	NULL
;	NULL
oscillations	NULL
were	NULL
reversibly	NULL
inhibited	NULL
by	NULL
the	NULL
application	NULL
of	NULL
50	NULL
uM	NULL
progesterone	NULL
to	NULL
the	NULL
bath	NULL
(	NULL
ba	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
[	NULL
Ca®+	NULL
]	NULL
;	NULL
oscillations	NULL
in	NULL
four	NULL
B3Z	NULL
cells	NULL
activated	NULL
by	NULL
settling	NULL
onto	NULL
coverslips	NULL
coated	NULL
with	NULL
anti-CD3-e	NULL
antibodies	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
a	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
b	NULL
)	NULL
of	NULL
50	NULL
M	NULL
progesterone	NULL
.	NULL

B	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
progesterone	NULL
blocks	NULL
Ca+	NULL
influx	NULL
subsequent	NULL
to	NULL
emptying	NULL
of	NULL
the	NULL
Ca®+*	NULL
stores	NULL
.	NULL

Progesterone	NULL
Depolanzes	NULL
the	NULL
Membrane	NULL
Potential	NULL
,	NULL
Reduang	NULL
the	NULL
Driving	NULL
Fore	NULL
for	NULL
C	NULL
&	NULL
@	NULL
*	NULL
Entry	NULL
.	NULL

C*	NULL
influx	NULL
depends	NULL
upon	NULL
the	NULL
opening	NULL
of	NULL
CR	NULL
AC	NULL
channels	NULL
and	NULL
upon	NULL
an	NULL
electrochem-ical	NULL
gradient	NULL
for	NULL
Ca®+*	NULL
entry	NULL
across	NULL
the	NULL
cell	NULL
membrane	NULL
.	NULL

The	NULL
negative	NULL
membrane	NULL
potential	NULL
supported	NULL
by	NULL
K*	NULL
channels	NULL
provides	NULL
the	NULL
electrical	NULL
component	NULL
of	NULL
the	NULL
driving	NULL
force	NULL
favoring	NULL
Ca®+*	NULL
entry	NULL
;	NULL
membrane	NULL
depolarization	NULL
would	NULL
reduce	NULL
this	NULL
driving	NULL
force	NULL
.	NULL

By	NULL
direct	NULL
measurement	NULL
during	NULL
perforated-patch	NULL
current-clamp	NULL
recording	NULL
,	NULL
we	NULL
found	NULL
that	NULL
progesterone	NULL
depolarizes	NULL
the	NULL
membrane	NULL
potential	NULL
,	NULL
E	NULL
,	NULL
,	NULL
.	NULL

Ky	NULL
channels	NULL
normally	NULL
maintain	NULL
the	NULL
resting	NULL
membrane	NULL
potential	NULL
of	NULL
T	NULL
lymphocytes	NULL
near	NULL
-60	NULL
mV	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Fig	NULL
.	NULL

4	NULL
A	NULL
illustrates	NULL
that	NULL
membrane	NULL
hyperpolarization	NULL
accompanies	NULL
TG	NULL
stimulation	NULL
(	NULL
from	NULL
-61	NULL
+	NULL
1.2	NULL
mV	NULL
,	NULL
n	NULL
=	NULL
3	NULL
;	NULL
to	NULL
-78	NULL
+	NULL
2.0	NULL
mV	NULL
,	NULL
r	NULL
=	NULL
11	NULL
)	NULL
.	NULL

The	NULL
hyperpolarization	NULL
that	NULL
follows	NULL
TG	NULL
stimulation	NULL
is	NULL
produced	NULL
by	NULL
activation	NULL
of	NULL
Kc	NULL
,	NULL
channels	NULL
during	NULL
the	NULL
rise	NULL
in	NULL
driving	NULL
FE	NULL
,	NULL
,	NULL
towards	NULL
the	NULL
K+	NULL
equilibrium	NULL
potential	NULL
of	NULL
~-80	NULL
mV	NULL
.	NULL

Progesterone	NULL
(	NULL
50	NULL
M	NULL
;	NULL
application	NULL
bar	NULL
,	NULL
Fig	NULL
.	NULL

4	NULL
A	NULL
)	NULL
not	NULL
only	NULL
reversed	NULL
the	NULL
hyperpolarization	NULL
,	NULL
but	NULL
also	NULL
resulted	NULL
in	NULL
depolarization	NULL
to	NULL
an	NULL
average	NULL
of	NULL
-41	NULL
+	NULL
4.3	NULL
mV	NULL
(	NULL
n	NULL
=	NULL
13	NULL
,	NULL
P	NULL
<	NULL
0.0001	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
progesterone	NULL
may	NULL
block	NULL
both	NULL
Ky	NULL
and	NULL
K..	NULL
,	NULL
channels	NULL
.	NULL

If	NULL
the	NULL
reduction	NULL
of	NULL
[	NULL
Ca	NULL
#	NULL
®+	NULL
]	NULL
;	NULL
by	NULL
progesterone	NULL
is	NULL
secondary	NULL
to	NULL
decreased	NULL
K*	NULL
current	NULL
,	NULL
then	NULL
restoration	NULL
of	NULL
a	NULL
K*	NULL
flux	NULL
across	NULL
the	NULL
cell	NULL
membrane	NULL
should	NULL
reverse	NULL
this	NULL
effect	NULL
of	NULL
progesterone	NULL
.	NULL

We	NULL
tested	NULL
this	NULL
hypothesis	NULL
by	NULL
using	NULL
the	NULL
K*	NULL
ionophore	NULL
,	NULL
valinomycin	NULL
,	NULL
to	NULL
hyperpolarize	NULL
E	NULL
,	NULL
,	NULL
.	NULL

In	NULL
the	NULL
experiment	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
B	NULL
,	NULL
30	NULL
wM	NULL
progesterone	NULL
reduced	NULL
the	NULL
plateau	NULL
in	NULL
[	NULL
C+	NULL
]	NULL
;	NULL
that	NULL
followed	NULL
TG	NULL
stimulation	NULL
.	NULL

The	NULL
subsequent	NULL
addition	NULL
of	NULL
valinomycin	NULL
in	NULL
the	NULL
continued	NULL
presence	NULL
of	NULL
progesterone	NULL
resulted	NULL
in	NULL
an	NULL
increase	NULL
of	NULL
[	NULL
Ca	NULL
``	NULL
+	NULL
]	NULL
;	NULL
.	NULL

Thus	NULL
,	NULL
Ca**+-imaging	NULL
and	NULL
current-clamp	NULL
experiments	NULL
demonstrate	NULL
that	NULL
progesterone	NULL
reduces	NULL
the	NULL
driving	NULL
force	NULL
for	NULL
Ca*+*	NULL
entry	NULL
,	NULL
an	NULL
effect	NULL
that	NULL
can	NULL
be	NULL
reversed	NULL
by	NULL
reestablishing	NULL
K*	NULL
efflux	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
progesterone	NULL
may	NULL
affect	NULL
[	NULL
Ca	NULL
``	NULL
+*	NULL
]	NULL
;	NULL
and	NULL
gene	NULL
expression	NULL
by	NULL
blocking	NULL
K*	NULL
channels	NULL
.	NULL

Progesterone	NULL
Blocks	NULL
Voltage-gated	NULL
K*	NULL
and	NULL
C	NULL
&	NULL
*	NULL
-activated	NULL
K+	NULL
Channels	NULL
in	NULL
T	NULL
Cells	NULL
:	NULL
Whole-cell	NULL
recording	NULL
with	NULL
the	NULL
patch-clamp	NULL
technique	NULL
permits	NULL
direct	NULL
measurement	NULL
of	NULL
several	NULL
types	NULL
of	NULL
channel	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
A	NULL
voltage	NULL
step	NULL
from	NULL
a	NULL
holding	NULL
potential	NULL
of	NULL
-80	NULL
to	NULL
+30	NULL
mV	NULL
elicits	NULL
rapidly	NULL
activating	NULL
Ky	NULL
currents	NULL
,	NULL
which	NULL
reach	NULL
a	NULL
peak	NULL
and	NULL
then	NULL
slowly	NULL
inacti-vate	NULL
.	NULL

K	NULL
,	NULL
,	NULL
currents	NULL
consist	NULL
of	NULL
two	NULL
components	NULL
,	NULL
a	NULL
predominant	NULL
fraction	NULL
encoded	NULL
by	NULL
homotetramers	NULL
of	NULL
the	NULL
Shaker-related	NULL
Kvl.3	NULL
gene	NULL
and	NULL
a	NULL
much	NULL
smaller	NULL
fraction	NULL
of	NULL
unknown	NULL
molecular	NULL
identity	NULL
(	NULL
for	NULL
a	NULL
review	NULL
,	NULL
see	NULL
reference	NULL
24	NULL
)	NULL
.	NULL

The	NULL
two	NULL
components	NULL
can	NULL
be	NULL
readily	NULL
distinguished	NULL
by	NULL
their	NULL
biophysical	NULL
and	NULL
pharmacological	NULL
properties	NULL
Kv1l.3	NULL
channels	NULL
are	NULL
blocked	NULL
by	NULL
nanomolar	NULL
concentrations	NULL
of	NULL
a	NULL
scorpion	NULL
toxin	NULL
,	NULL
charybdotoxin	NULL
(	NULL
CTX	NULL
)	NULL
,	NULL
and	NULL
undergo	NULL
cumulative	NULL
(	NULL
use-dependent	NULL
)	NULL
C-type	NULL
inactivation	NULL
during	NULL
repetitive	NULL
de-polarization	NULL
.	NULL

The	NULL
smaller	NULL
,	NULL
CT	NULL
X-resistant	NULL
current	NULL
does	NULL
not	NULL
exhibit	NULL
use-dependent	NULL
inactivation	NULL
.	NULL

Application	NULL
of	NULL
progesterone	NULL
rapidly	NULL
and	NULL
reversibly	NULL
reduces	NULL
Ky	NULL
currents	NULL
in	NULL
human	NULL
or	NULL
B3Z	NULL
T	NULL
cells	NULL
,	NULL
with	NULL
an	NULL
IC	NULL
,	NULL
,	NULL
of	NULL
29	NULL
+	NULL
2	NULL
wM	NULL
for	NULL
the	NULL
peak	NULL
K*	NULL
current	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Progesterone	NULL
accelerates	NULL
the	NULL
decline	NULL
of	NULL
K*	NULL
current	NULL
during	NULL
a	NULL
depolarizing	NULL
pulse	NULL
,	NULL
and	NULL
thus	NULL
the	NULL
block	NULL
Figure	NULL
3	NULL
.	NULL

-	NULL
Progesterone	NULL
reduces	NULL
the	NULL
[	NULL
Ca®*	NULL
]	NULL
;	NULL
plateau	NULL
evoked	NULL
by	NULL
TG	NULL
stimulation	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Average	NULL
[	NULL
Ca®+*	NULL
]	NULL
;	NULL
is	NULL
plotted	NULL
against	NULL
time	NULL
(	NULL
@	NULL
=	NULL
76	NULL
)	NULL
before	NULL
and	NULL
during	NULL
stimulation	NULL
with	NULL
1	NULL
pM	NULL
TG	NULL
(	NULL
@	NULL
row	NULL
)	NULL
.	NULL

TG	NULL
stimulated	NULL
Ca®*	NULL
influx	NULL
,	NULL
resulting	NULL
in	NULL
a	NULL
stable	NULL
rise	NULL
in	NULL
Addition	NULL
of	NULL
30	NULL
uM	NULL
progesterone	NULL
(	NULL
bar	NULL
)	NULL
reversibly	NULL
reduced	NULL
the	NULL
[	NULL
Ca®+	NULL
]	NULL
;	NULL
plateau	NULL
obtained	NULL
after	NULL
TG	NULL
stimulation	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
concentration	NULL
dependence	NULL
of	NULL
the	NULL
reduction	NULL
of	NULL
[	NULL
Ca®+	NULL
]	NULL
;	NULL
by	NULL
progesterone	NULL
is	NULL
plotted	NULL
for	NULL
TG-stimulated	NULL
cells	NULL
.	NULL

Calcium	NULL
levels	NULL
were	NULL
normalized	NULL
by	NULL
subtracting	NULL
the	NULL
resting	NULL
[	NULL
Ca	NULL
+	NULL
]	NULL
;	NULL
and	NULL
dividing	NULL
[	NULL
Ca+	NULL
]	NULL
;	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
progesterone	NULL
and	NULL
TG	NULL
by	NULL
[	NULL
C*	NULL
]	NULL
;	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
TG	NULL
alone	NULL
.	NULL

Data	NULL
are	NULL
presented	NULL
as	NULL
mean	NULL
+	NULL
SD	NULL
and	NULL
were	NULL
fitted	NULL
to	NULL
a	NULL
Hill	NULL
1600	NULL
B	NULL
.	NULL

,	NULL
1200	NULL
pots	NULL
H	NULL
W	NULL
0.8	NULL
~	NULL
f	NULL
i	NULL
J	NULL
!	NULL

*	NULL
I	NULL
£5	NULL
3	NULL
Nm	NULL
<	NULL
-	NULL
soo	NULL
$	NULL
s	NULL
i	NULL
g	NULL
,	NULL
0.6	NULL
<	NULL
f	NULL
o	NULL
or	NULL
f	NULL
B=	NULL
C	NULL
ts	NULL
;	NULL
t	NULL
0.4	NULL
*~*	NULL
400	NULL
f	NULL
6	NULL
|	NULL
}	NULL
C	NULL
_	NULL
)	NULL
[	NULL
d	NULL
--	NULL
t	NULL
-	NULL
r	NULL
r	NULL
0.0	NULL
t	NULL
0	NULL
1000	NULL
2000	NULL
3000	NULL
4000	NULL
1	NULL
Time	NULL
(	NULL
s	NULL
)	NULL
1596	NULL
t	NULL
10	NULL
Progesterone	NULL
(	NULL
uM	NULL
)	NULL
100	NULL
1000	NULL
equation	NULL
illustrated	NULL
by	NULL
the	NULL
smooth	NULL
curve	NULL
(	NULL
ICs	NULL
,	NULL
=	NULL
28	NULL
+	NULL
2.7	NULL
pM	NULL
and	NULL
n	NULL
=	NULL
1.3	NULL
+	NULL
0.2	NULL
)	NULL
.	NULL

Progesterone	NULL
Blocks	NULL
K*	NULL
Channels	NULL
and	NULL
T	NULL
Cell	NULL
Activation	NULL
A	NULL
Figure	NULL
0	NULL
Progesterane	NULL
4	NULL
.	NULL

Progesterone	NULL
reduces	NULL
the	NULL
driving	NULL
force	NULL
for	NULL
Ca®+	NULL
influx	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Current-clamp	NULL
recordings	NULL
using	NULL
the	NULL
perforated-patch	NULL
technique	NULL
were	NULL
performed	NULL
in	NULL
B3Z	NULL
cells	NULL
to	NULL
determine	NULL
the	NULL
effects	NULL
of	NULL
progesterone	NULL
on	NULL
E	NULL
,	NULL
,	NULL
.	NULL

This	NULL
panel	NULL
presents	NULL
a	NULL
representative	NULL
single-cell	NULL
recording	NULL
.	NULL

The	NULL
0	NULL
500	NULL
1000	NULL
Time	NULL
(	NULL
s	NULL
)	NULL
addition	NULL
of	NULL
1	NULL
M	NULL
TG	NULL
(	NULL
wrrow	NULL
)	NULL
hy-perpolarized	NULL
the	NULL
cell	NULL
from	NULL
the	NULL
8	NULL
a	NULL
va	NULL
resting	NULL
potential	NULL
(	NULL
-60	NULL
mV	NULL
)	NULL
to	NULL
near	NULL
the	NULL
K+	NULL
equilibrium	NULL
poten-	NULL
tial	NULL
(	NULL
~-80	NULL
mV	NULL
)	NULL
,	NULL
enhancing	NULL
the	NULL
driving	NULL
force	NULL
for	NULL
C*	NULL
influx	NULL
.	NULL

Subsequent	NULL
application	NULL
of	NULL
50	NULL
M	NULL
progesterone	NULL
depolarized	NULL
the	NULL
cell	NULL
to	NULL
-26	NULL
mV	NULL
,	NULL
resulting	NULL
in	NULL
a	NULL
reduction	NULL
of	NULL
the	NULL
driving	NULL
force	NULL
for	NULL
Ca*	NULL
influx	NULL
.	NULL

For	NULL
perforated-patch	NULL
recordings	NULL
,	NULL
the	NULL
tips	NULL
of	NULL
the	NULL
pipettes	NULL
were	NULL
filled	NULL
with	NULL
the	NULL
following	NULL
solution	NULL
(	NULL
in	NULL
mM	NULL
)	NULL
:	NULL
120	NULL
K	NULL
,	NULL
SO4	NULL
,	NULL
16	NULL
KCI	NULL
,	NULL
5	NULL
MgSO	NULL
,	NULL
,	NULL
10	NULL
Hepes	NULL
(	NULL
pH	NULL
7.2	NULL
)	NULL
.	NULL

A	NULL
stock	NULL
solution	NULL
of	NULL
nystatin	NULL
in	NULL
DMSO	NULL
(	NULL
25	NULL
g/	NULL
ml	NULL
)	NULL
was	NULL
prepared	NULL
daily	NULL
and	NULL
subsequently	NULL
diluted	NULL
in	NULL
the	NULL
pipette	NULL
solution	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
100	NULL
g/	NULL
ml	NULL
.	NULL

After	NULL
sonication	NULL
,	NULL
this	NULL
solution	NULL
was	NULL
used	NULL
for	NULL
backfilling	NULL
the	NULL
pipettes	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
reference	NULL
31	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Measurements	NULL
of	NULL
average	NULL
[	NULL
Ca®+	NULL
]	NULL
;	NULL
from	NULL
B3Z	NULL
cells	NULL
(	NULL
n	NULL
=	NULL
37	NULL
)	NULL
.	NULL

After	NULL
the	NULL
addition	NULL
of	NULL
1	NULL
uM	NULL
TG	NULL
(	NULL
arow	NULL
)	NULL
,	NULL
[	NULL
Ca°+	NULL
]	NULL
;	NULL
rose	NULL
from	NULL
a	NULL
resting	NULL
level	NULL
of	NULL
70	NULL
+	NULL
30	NULL
nM	NULL
to	NULL
a	NULL
plateau	NULL
of	NULL
1.3	NULL
+	NULL
0.4	NULL
uM	NULL
.	NULL

Progesterone	NULL
(	NULL
30	NULL
uM	NULL
)	NULL
reduced	NULL
the	NULL
[	NULL
Ca®+	NULL
]	NULL
;	NULL
to	NULL
approximately	NULL
half	NULL
of	NULL
plateau	NULL
concentration	NULL
,	NULL
an	NULL
effect	NULL
that	NULL
was	NULL
completely	NULL
reversed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
2	NULL
M	NULL
valinomycin	NULL
.	NULL

Application	NULL
bars	NULL
,	NULL
The	NULL
additions	NULL
of	NULL
progesterone	NULL
and	NULL
valinomycin	NULL
to	NULL
the	NULL
bath	NULL
.	NULL

[	NULL
64	NULL
1	NULL
,	NULL
(	NULL
M	NULL
)	NULL
o	NULL
1000	NULL
2000	NULL
2000	NULL
Time	NULL
(	NULL
s	NULL
)	NULL
is	NULL
more	NULL
potent	NULL
when	NULL
evaluated	NULL
at	NULL
the	NULL
end	NULL
of	NULL
a	NULL
200-ms	NULL
pulse	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
C	NULL
,	NULL
filled	NULL
triangles	NULL
)	NULL
.	NULL

The	NULL
apparent	NULL
increased	NULL
rate	NULL
of	NULL
channel	NULL
inactivation	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
suggests	NULL
that	NULL
progesterone	NULL
may	NULL
preferentially	NULL
bind	NULL
to	NULL
and	NULL
block	NULL
the	NULL
open	NULL
or	NULL
inactivated	NULL
Kyv1.3	NULL
channel	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
steady-state	NULL
inactivation	NULL
enhances	NULL
the	NULL
block	NULL
by	NULL
progesterone	NULL
,	NULL
we	NULL
inactivated	NULL
a	NULL
significant	NULL
fraction	NULL
of	NULL
Kv1.3	NULL
channels	NULL
by	NULL
decreasing	NULL
the	NULL
holding	NULL
potential	NULL
from	NULL
-80	NULL
to	NULL
-50	NULL
mV	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
A	NULL
,	NULL
progesterone	NULL
(	NULL
30	NULL
M	NULL
)	NULL
reduced	NULL
the	NULL
peak	NULL
Kv1l.3	NULL
currents	NULL
more	NULL
potently	NULL
when	NULL
the	NULL
holding	NULL
potential	NULL
was	NULL
-50	NULL
mV	NULL
(	NULL
70	NULL
%	NULL
block	NULL
;	NULL
see	NULL
open	NULL
arde	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
C	NULL
)	NULL
than	NULL
when	NULL
the	NULL
holding	NULL
potential	NULL
was	NULL
-80	NULL
mV	NULL
(	NULL
45	NULL
%	NULL
block	NULL
)	NULL
,	NULL
demonstrating	NULL
that	NULL
channel	NULL
inactivation	NULL
effectively	NULL
enhances	NULL
the	NULL
block	NULL
of	NULL
Kyv1.3	NULL
currents	NULL
by	NULL
progesterone	NULL
.	NULL

During	NULL
antigen-induced	NULL
oscillations	NULL
of	NULL
[	NULL
Ca	NULL
``	NULL
+	NULL
]	NULL
;	NULL
,	NULL
Kv1.3	NULL
channels	NULL
would	NULL
un-	NULL
C	NULL
A	NULL
Human	NULL
T	NULL
cell	NULL
B	NULL
B3Z	NULL
cell	NULL
Prog	NULL
.	NULL

(	NULL
uM	NULL
)	NULL
o	NULL
$	NULL
10	NULL
3	NULL
30	NULL
E	NULL
100	NULL
€	NULL
100	NULL
pa	NULL
[	NULL
__	NULL
200	NULL
pA	NULL
L	NULL
50	NULL
ms	NULL
50	NULL
ms	NULL
1	NULL
Figure	NULL
6	NULL
.	NULL

-	NULL
Inactivation	NULL
enhances	NULL
Ky	NULL
block	NULL
by	NULL
progesterone	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Ky	NULL
currents	NULL
were	NULL
elicited	NULL
by	NULL
A	NULL
steps	NULL
to	NULL
+30	NULL
mV	NULL
from	NULL
holding	NULL
potential	NULL
of	NULL
-80	NULL
mV	NULL
(	NULL
/	NULL
,	NULL
3	NULL
)	NULL
or	NULL
-50	NULL
mV	NULL
(	NULL
2	NULL
,	NULL
4	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
J	NULL
,	NULL
1	NULL
2	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
of	NULL
30	NULL
pM	NULL
progesterone	NULL
.	NULL

Solutions	NULL
used	NULL
are	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Use-dependent	NULL
block	NULL
of	NULL
voltage-gated	NULL
K*	NULL
currents	NULL
.	NULL

Current	NULL
responses	NULL
were	NULL
elicited	NULL
by	NULL
repetitive	NULL
voltage	NULL
pulses	NULL
from	NULL
-80	NULL
to	NULL
+30	NULL
mV	NULL
separated	NULL
by	NULL
20	NULL
s.	NULL
Normalized	NULL
peak	NULL
current	NULL
amplitudes	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
BB	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
¥	NULL
)	NULL
of	NULL
67	NULL
M	NULL
progesterone	NULL
were	NULL
plotted	NULL
against	NULL
time	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Time	NULL
course	NULL
of	NULL
recovery	NULL
from	NULL
inactivation	NULL
in	NULL
a	NULL
B3Z	NULL
cell	NULL
before	NULL
and	NULL
during	NULL
application	NULL
of	NULL
60	NULL
uM	NULL
progesterone	NULL
.	NULL

Pairs	NULL
of	NULL
200-ms	NULL
pulses	NULL
to	NULL
+30	NULL
mV	NULL
were	NULL
applied	NULL
from	NULL
a	NULL
holding	NULL
potential	NULL
of	NULL
-80	NULL
mV	NULL
.	NULL

The	NULL
graph	NULL
shows	NULL
the	NULL
ratio	NULL
of	NULL
peak	NULL
current	NULL
during	NULL
the	NULL
second	NULL
pulse	NULL
to	NULL
the	NULL
I	NULL
peak	NULL
current	NULL
during	NULL
the	NULL
first	NULL
as	NULL
!	NULL

!	NULL

|	NULL
pulse	NULL
,	NULL
plotted	NULL
as	NULL
a	NULL
function	NULL
of	NULL
the	NULL
y	NULL
time	NULL
interval	NULL
between	NULL
the	NULL
pulses	NULL
.	NULL

Data	NULL
were	NULL
fitted	NULL
by	NULL
single	NULL
expo-nentials	NULL
with	NULL
time	NULL
constants	NULL
of	NULL
4	NULL
s	NULL
for	NULL
control	NULL
(	NULL
@	NULL
@	NULL
)	NULL
and	NULL
39	NULL
s	NULL
for	NULL
progesterone	NULL
(	NULL
¥	NULL
)	NULL
.	NULL

Relative	NULL
K	NULL
,	NULL
Current	NULL
Time	NULL
(	NULL
s	NULL
)	NULL
Relative	NULL
K	NULL
,	NULL
Current	NULL
00	NULL
Time	NULL
(	NULL
s	NULL
)	NULL
dergo	NULL
repetitive	NULL
cycles	NULL
of	NULL
activation	NULL
,	NULL
inactivation	NULL
,	NULL
and	NULL
recovery	NULL
as	NULL
the	NULL
membrane	NULL
potential	NULL
fluctuates	NULL
Activation	NULL
cycles	NULL
can	NULL
result	NULL
in	NULL
frequency	NULL
or	NULL
use-dependent	NULL
inhibition	NULL
if	NULL
the	NULL
interval	NULL
between	NULL
depolarizations	NULL
is	NULL
less	NULL
than	NULL
the	NULL
time	NULL
required	NULL
for	NULL
full	NULL
recovery	NULL
from	NULL
inactivation	NULL
;	NULL
normally	NULL
,	NULL
pulse	NULL
intervals	NULL
of	NULL
>	NULL
20	NULL
s	NULL
allow	NULL
full	NULL
recovery	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
progesterone	NULL
,	NULL
Kvl.3	NULL
currents	NULL
steadily	NULL
declined	NULL
during	NULL
repetitive	NULL
pulsing	NULL
,	NULL
because	NULL
channel	NULL
inactivation	NULL
recovers	NULL
10-fold	NULL
more	NULL
slowly	NULL
,	NULL
resulting	NULL
in	NULL
accumulation	NULL
of	NULL
channels	NULL
in	NULL
the	NULL
inactivated	NULL
state	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

We	NULL
also	NULL
examined	NULL
the	NULL
effects	NULL
of	NULL
progesterone	NULL
on	NULL
the	NULL
smaller	NULL
component	NULL
of	NULL
Ky	NULL
current	NULL
by	NULL
selectively	NULL
blocking	NULL
the	NULL
Kv1.3	NULL
component	NULL
with	NULL
100	NULL
nM	NULL
CTX	NULL
.	NULL

At	NULL
this	NULL
dose	NULL
,	NULL
we	NULL
expect	NULL
a	NULL
residual	NULL
Kv1.3	NULL
current	NULL
of	NULL
only	NULL
2	NULL
%	NULL
that	NULL
in	NULL
the	NULL
ab-	NULL
Figure	NULL
5	NULL
.	NULL

-	NULL
Progesterone	NULL
blocks	NULL
Ky	NULL
channels	NULL
Whole-cell	NULL
currents	NULL
were	NULL
measured	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
A	NULL
)	NULL
and	NULL
B3Z	NULL
cells	NULL
(	NULL
B	NULL
)	NULL
during	NULL
200-ms	NULL
voltage	NULL
pulses	NULL
from	NULL
a	NULL
holding	NULL
potential	NULL
of	NULL
-80	NULL
mV	NULL
to	NULL
+30	NULL
mV	NULL
applied	NULL
every	NULL
30	NULL
s.	NULL
The	NULL
pipette	NULL
solution	NULL
contained	NULL
(	NULL
in	NULL
mM	NULL
)	NULL
:	NULL
160	NULL
K+*	NULL
aspartate	NULL
,	NULL
2	NULL
MgC	NULL
)	NULL
,	NULL
1	NULL
CaC	NULL
)	NULL
,	NULL
,	NULL
10	NULL
EGTA	NULL
,	NULL
10	NULL
Hepes	NULL
(	NULL
pH	NULL
7.2	NULL
)	NULL
.	NULL

Currents	NULL
are	NULL
shown	NULL
before	NULL
and	NULL
during	NULL
bath	NULL
application	NULL
of	NULL
10	NULL
,	NULL
30	NULL
,	NULL
or	NULL
100	NULL
M	NULL
progesterone	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Concentration	NULL
dependence	NULL
for	NULL
the	NULL
reduction	NULL
of	NULL
Ky	NULL
currents	NULL
by	NULL
progesterone	NULL
.	NULL

Peak	NULL
current	NULL
amplitudes	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
A	NULL
)	NULL
and	NULL
B3Z	NULL
cells	NULL
(	NULL
0	NULL
)	NULL
were	NULL
analyzed	NULL
and	NULL
plotted	NULL
against	NULL
progesterone	NULL
con-centration	NULL
.	NULL

Data	NULL
points	NULL
for	NULL
B3Z	NULL
and	NULL
human	NULL
T	NULL
cells	NULL
overlie	NULL
each	NULL
other	NULL
at	NULL
most	NULL
concentrations	NULL
.	NULL

For	NULL
human	NULL
10	NULL
100	NULL
[	NULL
Progesterone	NULL
]	NULL
(	NULL
uM	NULL
)	NULL
T	NULL
cells	NULL
,	NULL
the	NULL
current	NULL
at	NULL
the	NULL
end	NULL
of	NULL
the	NULL
200-ms	NULL
pulse	NULL
(	NULL
&	NULL
)	NULL
was	NULL
also	NULL
plotted	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
effect	NULL
of	NULL
depolarization	NULL
on	NULL
progesterone	NULL
block	NULL
,	NULL
E	NULL
,	NULL
,	NULL
,	NULL
was	NULL
held	NULL
at	NULL
-50	NULL
mV	NULL
(	NULL
O	NULL
)	NULL
.	NULL

Data	NULL
were	NULL
normalized	NULL
to	NULL
control	NULL
currents	NULL
measured	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
progesterone	NULL
and	NULL
presented	NULL
as	NULL
mean	NULL
+	NULL
SD	NULL
.	NULL

The	NULL
line	NULL
represents	NULL
a	NULL
fit	NULL
using	NULL
a	NULL
Hill	NULL
equation	NULL
with	NULL
an	NULL
ICs	NULL
,	NULL
of	NULL
29	NULL
+	NULL
2	NULL
pM	NULL
and	NULL
n	NULL
=	NULL
2.1	NULL
+	NULL
0.4	NULL
.	NULL

1597	NULL
_	NULL
Ehring	NULL
et	NULL
al	NULL
.	NULL

A	NULL
E	NULL
§	NULL
10	NULL
~-a-E	NULL
m	NULL
G	NULL
os	NULL
.\./	NULL
NTs	NULL
Ay	NULL
a*	NULL
CTX	NULL
l	NULL
\o	NULL
os	NULL
®	NULL
&	NULL
0.4	NULL
$	NULL
~	NULL
.	NULL

s	NULL
*	NULL
Control	NULL
E	NULL
5	NULL
£-Z	NULL
0	NULL
2	NULL
a	NULL
s	NULL
8	NULL
10	NULL
Time	NULL
(	NULL
s	NULL
)	NULL
B	NULL
Control	NULL
200	NULL
pA	NULL
L	NULL
RU4ASG	NULL
Progesterone	NULL
25	NULL
m§	NULL
C	NULL
CTX	NULL
CTX	NULL
+	NULL
RU48G	NULL
10	NULL
pA	NULL
25	NULL
ms	NULL
CTX	NULL
+	NULL
Progesterone	NULL
Figure	NULL
7	NULL
.	NULL

-	NULL
Progesterone	NULL
blocks	NULL
CT	NULL
X-resistant	NULL
Ky	NULL
channels	NULL
.	NULL

Pipette	NULL
solution	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Current	NULL
responses	NULL
of	NULL
the	NULL
total	NULL
Ky	NULL
current	NULL
(	NULL
@	NULL
)	NULL
and	NULL
the	NULL
CTX-resistant	NULL
current	NULL
(	NULL
lil	NULL
)	NULL
to	NULL
repetitive	NULL
voltage	NULL
pulses	NULL
from	NULL
-80	NULL
to	NULL
+30	NULL
mV	NULL
separated	NULL
by	NULL
1	NULL
s.	NULL
At	NULL
this	NULL
rate	NULL
of	NULL
pulsing	NULL
,	NULL
Kv1.3	NULL
channels	NULL
undergo	NULL
cumulative	NULL
inactivation	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
normalized	NULL
peak	NULL
current	NULL
amplitudes	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
CTX	NULL
(	NULL
R	NULL
)	NULL
.	NULL

With	NULL
100	NULL
nM	NULL
CTX	NULL
present	NULL
(	NULL
@	NULL
)	NULL
,	NULL
the	NULL
remaining	NULL
current	NULL
does	NULL
not	NULL
decline	NULL
during	NULL
repetitive	NULL
pulsing	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Progesterone	NULL
or	NULL
RU	NULL
486	NULL
(	NULL
50	NULL
pM	NULL
)	NULL
blocks	NULL
the	NULL
Ky	NULL
component	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Progesterone	NULL
blocks	NULL
the	NULL
CTX-resistant	NULL
component	NULL
of	NULL
Ky	NULL
current	NULL
more	NULL
than	NULL
RU	NULL
486	NULL
.	NULL

100	NULL
nM	NULL
CTX	NULL
was	NULL
preapplied	NULL
in	NULL
R	NULL
inger	NULL
in	NULL
order	NULL
to	NULL
block	NULL
Kv1.3	NULL
channels	NULL
.	NULL

sence	NULL
of	NULL
CTX	NULL
.	NULL

However	NULL
,	NULL
in	NULL
11	NULL
cells	NULL
examined	NULL
in	NULL
this	NULL
series	NULL
of	NULL
experiments	NULL
and	NULL
in	NULL
previous	NULL
work	NULL
(	NULL
21	NULL
)	NULL
,	NULL
5-20	NULL
%	NULL
of	NULL
the	NULL
K	NULL
,	NULL
,	NULL
current	NULL
remains	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CTX	NULL
.	NULL

This	NULL
residual	NULL
CT	NULL
X-resistant	NULL
current	NULL
does	NULL
not	NULL
undergo	NULL
use-dependent	NULL
inactivation	NULL
during	NULL
repetitive	NULL
depolarizing	NULL
pulses	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
A	NULL
)	NULL
.	NULL

Fig	NULL
.	NULL

7	NULL
B	NULL
demonstrates	NULL
that	NULL
the	NULL
larger	NULL
,	NULL
use-dependent	NULL
,	NULL
CT	NULL
X-sensitive	NULL
component	NULL
of	NULL
Ky	NULL
current	NULL
is	NULL
blocked	NULL
either	NULL
by	NULL
progesterone	NULL
or	NULL
by	NULL
RU	NULL
486	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7	NULL
C	NULL
,	NULL
most	NULL
of	NULL
the	NULL
CTX-resistant	NULL
current	NULL
is	NULL
also	NULL
blocked	NULL
by	NULL
50	NULL
M	NULL
progesterone	NULL
,	NULL
whereas	NULL
RU	NULL
486	NULL
at	NULL
the	NULL
same	NULL
concentration	NULL
is	NULL
less	NULL
effective	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
progesterone	NULL
blocks	NULL
both	NULL
the	NULL
predominant	NULL
Kv1.3	NULL
component	NULL
and	NULL
the	NULL
CTX-resistant	NULL
component	NULL
of	NULL
Ky	NULL
current	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
that	NULL
RU	NULL
486	NULL
blocks	NULL
primarily	NULL
the	NULL
Kv1.3	NULL
component	NULL
.	NULL

K.	NULL
,	NULL
channels	NULL
hyperpolarize	NULL
the	NULL
membrane	NULL
potential	NULL
of	NULL
T	NULL
cells	NULL
during	NULL
the	NULL
[	NULL
Ca+	NULL
]	NULL
;	NULL
signal	NULL
,	NULL
effectively	NULL
counteracting	NULL
the	NULL
depolarizing	NULL
effects	NULL
of	NULL
influx	NULL
.	NULL

K	NULL
,	NULL
channels	NULL
are	NULL
volt-age-independent	NULL
and	NULL
highly	NULL
sensitive	NULL
to	NULL
a	NULL
rise	NULL
in	NULL
[	NULL
C¥	NULL
#	NULL
+	NULL
]	NULL
;	NULL
,	NULL
with	NULL
half-activation	NULL
at	NULL
~400	NULL
nM	NULL
and	NULL
a	NULL
steep	NULL
[	NULL
Ca	NULL
``	NULL
+*	NULL
]	NULL
;	NULL
de-pendence	NULL
,	NULL
suggesting	NULL
that	NULL
at	NULL
least	NULL
four	NULL
Ca®*	NULL
ions	NULL
must	NULL
bind	NULL
to	NULL
open	NULL
the	NULL
channel	NULL
(	NULL
for	NULL
a	NULL
review	NULL
,	NULL
see	NULL
reference	NULL
24	NULL
)	NULL
.	NULL

Based	NULL
upon	NULL
biophysical	NULL
characterization	NULL
and	NULL
its	NULL
expression	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
the	NULL
K	NULL
,	NULL
,	NULL
channel	NULL
in	NULL
T	NULL
cells	NULL
is	NULL
encoded	NULL
by	NULL
the	NULL
gene	NULL
hKCa4	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Intracellular	NULL
dialysis	NULL
of	NULL
B3Z	NULL
or	NULL
ac	NULL
1598	NULL
tivated	NULL
human	NULL
T	NULL
cells	NULL
with	NULL
solutions	NULL
containing	NULL
1	NULL
pM	NULL
Ca®+	NULL
activated	NULL
a	NULL
large	NULL
K*	NULL
current	NULL
that	NULL
was	NULL
evident	NULL
in	NULL
voltage	NULL
ramps	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
A	NULL
)	NULL
.	NULL

Progesterone	NULL
blocked	NULL
K.	NULL
,	NULL
channels	NULL
with	NULL
an	NULL
IC	NULL
;	NULL
,	NULL
value	NULL
of	NULL
113	NULL
+	NULL
9	NULL
mM	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
B	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
progesterone	NULL
blocks	NULL
the	NULL
Ky	NULL
currents	NULL
more	NULL
potently	NULL
than	NULL
the	NULL
K	NULL
,	NULL
currents	NULL
in	NULL
T	NULL
cells	NULL
In	NULL
contrast	NULL
,	NULL
the	NULL
progesterone	NULL
antagonist	NULL
RU	NULL
486	NULL
was	NULL
consistently	NULL
more	NULL
potent	NULL
than	NULL
progesterone	NULL
in	NULL
blocking	NULL
Ky	NULL
,	NULL
current	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
C	NULL
)	NULL
.	NULL

These	NULL
experiments	NULL
demonstrate	NULL
some	NULL
degree	NULL
of	NULL
selectivity	NULL
of	NULL
the	NULL
two	NULL
components	NULL
of	NULL
Ky	NULL
current	NULL
and	NULL
the	NULL
K	NULL
,	NULL
current	NULL
for	NULL
progesterone	NULL
and	NULL
RU	NULL
486	NULL
.	NULL

Selectivity	NULL
of	NULL
Progesterone	NULL
for	NULL
K	NULL
,	NULL
Channels	NULL
:	NULL
Progesterone	NULL
Does	NULL
Not	NULL
Block	NULL
CRAC	NULL
or	NULL
Chloride	NULL
Channels	NULL
in	NULL
T	NULL
Cells	NULL
The	NULL
results	NULL
from	NULL
patch-clamp	NULL
experiments	NULL
suggested	NULL
that	NULL
progesterone	NULL
,	NULL
RU	NULL
486	NULL
,	NULL
and	NULL
perhaps	NULL
other	NULL
steroid	NULL
hormones	NULL
might	NULL
block	NULL
several	NULL
K*	NULL
channel	NULL
types	NULL
,	NULL
albeit	NULL
with	NULL
rather	NULL
low	NULL
affinity	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
screened	NULL
a	NULL
panel	NULL
of	NULL
steroids	NULL
on	NULL
the	NULL
Ky	NULL
and	NULL
Kc	NULL
,	NULL
channels	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

Most	NULL
of	NULL
the	NULL
compounds	NULL
tested	NULL
either	NULL
had	NULL
no	NULL
effect	NULL
or	NULL
were	NULL
less	NULL
effective	NULL
than	NULL
progesterone	NULL
in	NULL
blocking	NULL
Ky	NULL
or	NULL
Kq	NULL
,	NULL
currents	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
screened	NULL
several	NULL
channel	NULL
types	NULL
,	NULL
including	NULL
both	NULL
cloned	NULL
and	NULL
native	NULL
channels	NULL
expressed	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
cell	NULL
lines	NULL
,	NULL
for	NULL
block	NULL
by	NULL
progesterone	NULL
,	NULL
as	NULL
summarized	NULL
in	NULL
Table	NULL
2	NULL
.	NULL

Progesterone	NULL
blocks	NULL
several	NULL
Kv1l	NULL
family	NULL
members	NULL
,	NULL
Progesterone	NULL
(	NULL
rM	NULL
)	NULL
100	NULL
300	NULL
-	NULL
20	NULL
Voltage	NULL
(	NULL
mV	NULL
)	NULL
800	NULL
Figure	NULL
8	NULL
.	NULL

Concentration-dependent	NULL
inhibition	NULL
of	NULL
K	NULL
;	NULL
,	NULL
current	NULL
in	NULL
B3Z	NULL
cells	NULL
by	NULL
progesterone	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Kc	NULL
,	NULL
currents	NULL
were	NULL
activated	NULL
by	NULL
dialyzing	NULL
the	NULL
cell	NULL
with	NULL
a	NULL
solution	NULL
containing	NULL
(	NULL
in	NULL
mM	NULL
)	NULL
140	NULL
K*	NULL
aspartate	NULL
,	NULL
2	NULL
MgC1	NULL
,	NULL
,	NULL
7.8	NULL
CaC	NULL
)	NULL
,	NULL
10	NULL
EGTA	NULL
,	NULL
5	NULL
Hepes	NULL
(	NULL
pH	NULL
7.2	NULL
)	NULL
.	NULL

The	NULL
nominal	NULL
free	NULL
C*	NULL
concentration	NULL
of	NULL
this	NULL
solution	NULL
was	NULL
1	NULL
pM	NULL
,	NULL
assuming	NULL
a	NULL
dissociation	NULL
constant	NULL
for	NULL
EGTA	NULL
and	NULL
Ca*	NULL
of	NULL
107	NULL
``	NULL
at	NULL
pH	NULL
7.2	NULL
.	NULL

Ca®*-activated	NULL
K*	NULL
currents	NULL
were	NULL
evoked	NULL
by	NULL
voltage	NULL
ramps	NULL
of	NULL
200-ms	NULL
duration	NULL
from	NULL
-120	NULL
to	NULL
+50	NULL
mV	NULL
every	NULL
30	NULL
s.	NULL
Application	NULL
of	NULL
progesterone	NULL
at	NULL
different	NULL
concentrations	NULL
(	NULL
indi-cated	NULL
at	NULL
the	NULL
right	NULL
of	NULL
each	NULL
trace	NULL
)	NULL
inhibited	NULL
the	NULL
Kc	NULL
,	NULL
current	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Concentration-response	NULL
curve	NULL
for	NULL
progesterone	NULL
block	NULL
of	NULL
Ky	NULL
,	NULL
currents	NULL
(	NULL
@	NULL
)	NULL
.	NULL

The	NULL
slope	NULL
conductance	NULL
between	NULL
-100	NULL
and	NULL
-60	NULL
mV	NULL
was	NULL
used	NULL
as	NULL
a	NULL
measure	NULL
of	NULL
the	NULL
K	NULL
,	NULL
,	NULL
conductance	NULL
to	NULL
avoid	NULL
contamination	NULL
by	NULL
Ky	NULL
currents	NULL
.	NULL

Data	NULL
were	NULL
normalized	NULL
to	NULL
the	NULL
conductance	NULL
measured	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
progesterone	NULL
and	NULL
presented	NULL
as	NULL
mean	NULL
+	NULL
SD	NULL
.	NULL

The	NULL
line	NULL
represents	NULL
the	NULL
fit	NULL
to	NULL
a	NULL
Hill	NULL
equation	NULL
with	NULL
IC	NULL
,	NULL
=	NULL
113	NULL
M	NULL
and	NULL
n	NULL
=	NULL
1.2	NULL
.	NULL

Block	NULL
of	NULL
Ke	NULL
,	NULL
channels	NULL
by	NULL
60	NULL
M	NULL
RU	NULL
486	NULL
(	NULL
C	NULL
)	NULL
is	NULL
shown	NULL
for	NULL
comparison	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Comparison	NULL
of	NULL
progesterone	NULL
and	NULL
RU	NULL
486	NULL
.	NULL

Slope	NULL
conductance	NULL
values	NULL
at	NULL
-80	NULL
mV	NULL
illustrate	NULL
activation	NULL
and	NULL
block	NULL
of	NULL
the	NULL
Ke	NULL
,	NULL
current	NULL
by	NULL
RU	NULL
486	NULL
and	NULL
progesterone	NULL
,	NULL
each	NULL
applied	NULL
at	NULL
60	NULL
.M	NULL
.	NULL

Relative	NULL
K.	NULL
,	NULL
Current	NULL
M	NULL
to	NULL
100	NULL
Progesterone	NULL
(	NULL
M	NULL
)	NULL
RU48G	NULL
-	NULL
Progesterone	NULL
Slope	NULL
Conductance	NULL
(	NULL
nS	NULL
)	NULL
Time	NULL
(	NULL
s	NULL
)	NULL
Progesterone	NULL
Blocks	NULL
K*	NULL
Channels	NULL
and	NULL
T	NULL
Cell	NULL
Activation	NULL
Table	NULL
1	NULL
.	NULL

-	NULL
Percent	NULL
Inhibition	NULL
of	NULL
Ky	NULL
,	NULL
and	NULL
K¢	NULL
,	NULL
,	NULL
Channels	NULL
by	NULL
Steroids	NULL
(	NULL
60	NULL
uM	NULL
)	NULL
Progesterone	NULL
RU	NULL
486	NULL
Estradiol	NULL
Testosterone	NULL
Cortisol	NULL
DHEA	NULL
OHP	NULL
Aldosterone	NULL
Ky	NULL
77	NULL
+	NULL
8	NULL
61	NULL
+	NULL
15	NULL
24	NULL
+	NULL
7	NULL
17	NULL
+	NULL
12	NULL
13	NULL
+	NULL
4	NULL
10	NULL
+	NULL
6	NULL
12	NULL
+	NULL
6	NULL
12	NULL
+	NULL
13	NULL
Koa	NULL
34	NULL
+	NULL
11	NULL
55	NULL
+	NULL
12	NULL
8	NULL
+	NULL
10	NULL
4	NULL
+	NULL
7	NULL
0.0	NULL
+	NULL
0.1	NULL
0.4	NULL
+	NULL
0.7	NULL
2	NULL
+	NULL
4	NULL
6	NULL
+	NULL
7	NULL
Currents	NULL
through	NULL
Ky	NULL
channels	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
were	NULL
evoked	NULL
by	NULL
depolarizing	NULL
pulses	NULL
to	NULL
+30	NULL
mV	NULL
,	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

K	NULL
,	NULL
channels	NULL
in	NULL
activated	NULL
human	NULL
T	NULL
cells	NULL
were	NULL
opened	NULL
by	NULL
1	NULL
uM	NULL
[	NULL
Ca®*	NULL
]	NULL
;	NULL
,	NULL
with	NULL
currents	NULL
measured	NULL
during	NULL
voltage-ramp	NULL
stimuli	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

8	NULL
.	NULL

Data	NULL
are	NULL
presented	NULL
as	NULL
mean	NULL
+	NULL
SD	NULL
,	NULL
with	NULL
at	NULL
least	NULL
three	NULL
separate	NULL
experiments	NULL
for	NULL
each	NULL
compound	NULL
tested	NULL
at	NULL
60	NULL
uM	NULL
,	NULL
and	NULL
represent	NULL
the	NULL
percent	NULL
inhibition	NULL
of	NULL
peak	NULL
Ky	NULL
currents	NULL
or	NULL
slope	NULL
conductances	NULL
of	NULL
K.	NULL
,	NULL
currents	NULL
near	NULL
-80	NULL
mV	NULL
.	NULL

DHEA	NULL
,	NULL
Dehydrocpiandrosterone	NULL
;	NULL
OHP	NULL
,	NULL
17	NULL
«	NULL
-hydroxy-4-pregnene-3,20-dione	NULL
.	NULL

including	NULL
Kv1.3	NULL
expressed	NULL
in	NULL
lymphocytes	NULL
as	NULL
the	NULL
predominant	NULL
Ky	NULL
current	NULL
,	NULL
as	NULL
well	NULL
as	NULL
Kv3.1	NULL
expressed	NULL
in	NULL
the	NULL
brain	NULL
and	NULL
in	NULL
certain	NULL
subsets	NULL
of	NULL
mouse	NULL
thymocytes	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
progesterone	NULL
had	NULL
very	NULL
little	NULL
effect	NULL
on	NULL
a	NULL
cloned	NULL
voltage-gated	NULL
Nat	NULL
channel	NULL
found	NULL
in	NULL
skeletal	NULL
muscle	NULL
,	NULL
or	NULL
on	NULL
a	NULL
strongly	NULL
inward	NULL
rectifying	NULL
K*	NULL
channel	NULL
found	NULL
in	NULL
RBL	NULL
cells	NULL
We	NULL
conclude	NULL
that	NULL
progesterone	NULL
is	NULL
a	NULL
broad	NULL
spectrum	NULL
,	NULL
low-affinity	NULL
K*	NULL
channel	NULL
blocker	NULL
.	NULL

In	NULL
further	NULL
experiments	NULL
on	NULL
Jurkat	NULL
T	NULL
lymphocytes	NULL
,	NULL
we	NULL
evaluated	NULL
effects	NULL
of	NULL
progesterone	NULL
on	NULL
CR	NULL
AC	NULL
and	NULL
CI-	NULL
channels	NULL
to	NULL
determine	NULL
if	NULL
modulation	NULL
of	NULL
these	NULL
channel	NULL
types	NULL
might	NULL
contribute	NULL
to	NULL
the	NULL
inhibition	NULL
of	NULL
Ca®*	NULL
signaling	NULL
.	NULL

During	NULL
whole-cell	NULL
patch-clamp	NULL
recordings	NULL
,	NULL
intracellular	NULL
dialysis	NULL
with	NULL
heavily	NULL
buffered	NULL
low-Ca	NULL
``	NULL
+	NULL
solutions	NULL
passively	NULL
depleted	NULL
the	NULL
intracellular	NULL
Ca+	NULL
stores	NULL
and	NULL
activated	NULL
CRAC	NULL
channels	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
A	NULL
)	NULL
.	NULL

After	NULL
maximal	NULL
activation	NULL
,	NULL
30	NULL
pM	NULL
progesterone	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
B	NULL
,	NULL
application	NULL
bar	NULL
)	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
amplitude	NULL
or	NULL
the	NULL
current-voltage	NULL
characteristics	NULL
(	NULL
n	NULL
=	NULL
6	NULL
cells	NULL
)	NULL
.	NULL

This	NULL
experiment	NULL
rules	NULL
out	NULL
direct	NULL
CRAC	NULL
channel	NULL
block	NULL
as	NULL
a	NULL
possible	NULL
contributor	NULL
to	NULL
the	NULL
inhibition	NULL
of	NULL
C	NULL
#	NULL
+	NULL
signaling	NULL
by	NULL
progesterone	NULL
;	NULL
instead	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
progesterone	NULL
blocks	NULL
Ca®*	NULL
signaling	NULL
by	NULL
inhibiting	NULL
K+	NULL
channels	NULL
,	NULL
indirectly	NULL
reducing	NULL
the	NULL
driving	NULL
force	NULL
for	NULL
Ca®*	NULL
entry	NULL
.	NULL

CI-	NULL
channels	NULL
have	NULL
also	NULL
been	NULL
implicated	NULL
in	NULL
lymphocyte	NULL
signaling	NULL
mechanisms	NULL
by	NULL
helping	NULL
to	NULL
maintain	NULL
E	NULL
,	NULL
,	NULL
during	NULL
T	NULL
cell	NULL
acti-	NULL
Table	NULL
2	NULL
.	NULL

-	NULL
Percent	NULL
Inhibition	NULL
of	NULL
Various	NULL
Channel	NULL
Types	NULL
by	NULL
Progesterone	NULL
vation	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
.	NULL

However	NULL
,	NULL
superfusion	NULL
of	NULL
B3Z	NULL
or	NULL
Jurkat	NULL
cells	NULL
with	NULL
50	NULL
M	NULL
progesterone	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
amplitude	NULL
or	NULL
the	NULL
current-voltage	NULL
characteristics	NULL
of	NULL
CI-	NULL
currents	NULL
induced	NULL
by	NULL
cell	NULL
swelling	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
,	NULL
C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

Discussion	NULL
In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
demonstrate	NULL
by	NULL
patch-clamp	NULL
measurement	NULL
that	NULL
progesterone	NULL
directly	NULL
blocks	NULL
Ky	NULL
and	NULL
K.	NULL
,	NULL
channels	NULL
,	NULL
but	NULL
not	NULL
Ca*®+*	NULL
or	NULL
CI-	NULL
channels	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
show	NULL
that	NULL
K*	NULL
channel	NULL
blockade	NULL
is	NULL
associated	NULL
with	NULL
membrane	NULL
depolarization	NULL
,	NULL
inhibition	NULL
of	NULL
Ca*	NULL
signaling	NULL
,	NULL
and	NULL
a	NULL
reduction	NULL
of	NULL
NF-AT-driven	NULL
gene	NULL
expression	NULL
.	NULL

Since	NULL
NF-	NULL
AT	NULL
links	NULL
activation	NULL
of	NULL
the	NULL
TCR	NULL
to	NULL
IL-2	NULL
produc-tion	NULL
,	NULL
interruption	NULL
of	NULL
these	NULL
signals	NULL
would	NULL
inhibit	NULL
production	NULL
of	NULL
the	NULL
major	NULL
proliferative	NULL
cytokine	NULL
for	NULL
T	NULL
cells	NULL
We	NULL
propose	NULL
that	NULL
K*	NULL
channel	NULL
blockade	NULL
provides	NULL
a	NULL
mechanism	NULL
contributing	NULL
to	NULL
the	NULL
immunosuppressive	NULL
effects	NULL
of	NULL
progesterone	NULL
.	NULL

The	NULL
rapid	NULL
onset	NULL
and	NULL
reversibility	NULL
of	NULL
Ky	NULL
channel	NULL
block	NULL
by	NULL
progesterone	NULL
is	NULL
incompatible	NULL
with	NULL
changes	NULL
in	NULL
mRNA	NULL
or	NULL
protein	NULL
synthesis	NULL
,	NULL
suggesting	NULL
that	NULL
these	NULL
effects	NULL
are	NULL
not	NULL
mediated	NULL
by	NULL
the	NULL
classical	NULL
steroid	NULL
receptor	NULL
pathway	NULL
(	NULL
40	NULL
)	NULL
.	NULL

The	NULL
progesterone	NULL
antagonist	NULL
RU	NULL
486	NULL
is	NULL
nearly	NULL
as	NULL
potent	NULL
as	NULL
progesterone	NULL
in	NULL
blocking	NULL
both	NULL
Ky	NULL
channels	NULL
and	NULL
gene	NULL
ex-pression	NULL
,	NULL
also	NULL
implicating	NULL
a	NULL
nongenomic	NULL
action	NULL
of	NULL
proges-	NULL
Cloned	NULL
channels	NULL
Gene	NULL
Kyvl.1	NULL
Kyvl.2	NULL
Kv1.3	NULL
Kv1.4	NULL
KyvI1.5	NULL
Kv3.1	NULL
hSKM1	NULL
Cell	NULL
type	NULL
L929	NULL
NGK1	NULL
L929	NULL
LTK	NULL
MEL	NULL
L929	NULL
HEK	NULL
31	NULL
+	NULL
6	NULL
45	NULL
+	NULL
10	NULL
44	NULL
+	NULL
9	NULL
23	NULL
+	NULL
8	NULL
25	NULL
+	NULL
2	NULL
53	NULL
+3	NULL
11	NULL
+	NULL
1	NULL
Native	NULL
channels	NULL
Channel	NULL
Ky	NULL
Ky	NULL
Ky	NULL
(	NULL
CTX	NULL
)	NULL
Koa	NULL
CRAC	NULL
CI-	NULL
Kir	NULL
Cell	NULL
type	NULL
Human	NULL
T	NULL
B3Z	NULL
Human	NULL
T	NULL
Human	NULL
T	NULL
,	NULL
act	NULL
.	NULL

Jurkat	NULL
T	NULL
Jurkat	NULL
T	NULL
RBL	NULL
50	NULL
+	NULL
6	NULL
40	NULL
+	NULL
10	NULL
70	NULL
+	NULL
20	NULL
34	NULL
+	NULL
11	NULL
0	NULL
0	NULL
4	NULL
+	NULL
12	NULL
The	NULL
panel	NULL
of	NULL
cloned	NULL
Ky	NULL
channels	NULL
was	NULL
provided	NULL
by	NULL
Dr.	NULL
K.	NULL
George	NULL
Chandy	NULL
(	NULL
Department	NULL
of	NULL
Physiology	NULL
and	NULL
Biophysics	NULL
,	NULL
University	NULL
of	NULL
California	NULL
,	NULL
Irvine	NULL
)	NULL
,	NULL
as	NULL
described	NULL
(	NULL
reference	NULL
55	NULL
)	NULL
.	NULL

The	NULL
voltage-gated	NULL
Nat	NULL
channel	NULL
clone	NULL
hSKM1	NULL
,	NULL
originally	NULL
derived	NULL
from	NULL
skeletal	NULL
muscle	NULL
,	NULL
was	NULL
made	NULL
by	NULL
Dr.	NULL
Frank	NULL
Lehmann-Horn	NULL
(	NULL
Department	NULL
of	NULL
General	NULL
Physiology	NULL
,	NULL
University	NULL
of	NULL
Ulm	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Peak	NULL
Na*	NULL
currents	NULL
were	NULL
evaluated	NULL
at	NULL
+10	NULL
mV	NULL
.	NULL

Ky	NULL
currents	NULL
were	NULL
evoked	NULL
by	NULL
depolarizing	NULL
pulses	NULL
,	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

CTX-resistant	NULL
Ky	NULL
channels	NULL
[	NULL
K	NULL
,	NULL
(	NULL
CTX	NULL
)	NULL
]	NULL
were	NULL
studied	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
100	NULL
nM	NULL
CTX	NULL
,	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

K	NULL
,	NULL
channels	NULL
were	NULL
activated	NULL
by	NULL
1	NULL
M	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

8	NULL
.	NULL

CRAC	NULL
and	NULL
C1~	NULL
channels	NULL
were	NULL
activated	NULL
by	NULL
Ca®+-store	NULL
depletion	NULL
or	NULL
by	NULL
cell	NULL
swelling	NULL
,	NULL
respectively	NULL
,	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

9	NULL
.	NULL

Inwardly	NULL
rectifying	NULL
K*	NULL
(	NULL
K	NULL
;	NULL
g	NULL
)	NULL
currents	NULL
were	NULL
evaluated	NULL
during	NULL
voltage-ramp	NULL
stimuli	NULL
.	NULL

In	NULL
each	NULL
case	NULL
,	NULL
progesterone	NULL
was	NULL
tested	NULL
at	NULL
30	NULL
uM	NULL
,	NULL
except	NULL
for	NULL
Ky	NULL
(	NULL
CTX	NULL
)	NULL
,	NULL
K	NULL
,	NULL
,	NULL
and	NULL
CI~	NULL
channels	NULL
tested	NULL
at	NULL
50	NULL
uM	NULL
.	NULL

Data	NULL
are	NULL
presented	NULL
as	NULL
mean	NULL
+	NULL
SD	NULL
,	NULL
with	NULL
at	NULL
least	NULL
three	NULL
separate	NULL
experiments	NULL
for	NULL
each	NULL
channel	NULL
type	NULL
.	NULL

1599	NULL
_	NULL
Ehring	NULL
et	NULL
al	NULL
.	NULL

Progesterone	NULL
lave	NULL
(	NULL
PA	NULL
)	NULL
Time	NULL
(	NULL
s	NULL
)	NULL
Progesterone	NULL
G	NULL
,	NULL
,	NULL
(	NULL
nS	NULL
)	NULL
40	NULL
40	NULL
Voltage	NULL
(	NULL
mV	NULL
)	NULL
05	NULL
Time	NULL
(	NULL
s	NULL
)	NULL
Figure	NULL
9	NULL
.	NULL

Progesterone	NULL
does	NULL
not	NULL
affect	NULL
CRAC	NULL
or	NULL
CIT	NULL
channels	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Whole-cell	NULL
recordings	NULL
of	NULL
Ca*	NULL
current	NULL
through	NULL
CRAC	NULL
channels	NULL
measured	NULL
during	NULL
voltage	NULL
ramps	NULL
from	NULL
-100	NULL
to	NULL
+40	NULL
mV	NULL
for	NULL
a	NULL
duration	NULL
of	NULL
200	NULL
ms	NULL
.	NULL

The	NULL
pipette	NULL
solution	NULL
contained	NULL
(	NULL
in	NULL
mM	NULL
)	NULL
128	NULL
Cst	NULL
aspartate	NULL
,	NULL
12	NULL
BAPTA	NULL
,	NULL
0.9	NULL
CaC	NULL
)	NULL
,	NULL
,	NULL
3.16	NULL
MgC	NULL
)	NULL
,	NULL
Hepes	NULL
(	NULL
pH	NULL
7.2	NULL
)	NULL
.	NULL

The	NULL
external	NULL
solution	NULL
had	NULL
the	NULL
following	NULL
composition	NULL
(	NULL
in	NULL
mM	NULL
)	NULL
:	NULL
150	NULL
NaMeSO	NULL
;	NULL
,	NULL
20	NULL
CaC	NULL
)	NULL
,	NULL
,	NULL
10	NULL
glucose	NULL
,	NULL
10	NULL
Hepes	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Time-dependent	NULL
changes	NULL
in	NULL
the	NULL
amplitude	NULL
of	NULL
the	NULL
current	NULL
measured	NULL
at	NULL
-80	NULL
mV	NULL
.	NULL

Arrows	NULL
,	NULL
R	NULL
epresentative	NULL
currents	NULL
recorded	NULL
before	NULL
store	NULL
depletion	NULL
(	NULL
7	NULL
)	NULL
,	NULL
and	NULL
after	NULL
maximal	NULL
induction	NULL
activation	NULL
of	NULL
CRAC	NULL
channels	NULL
,	NULL
while	NULL
superfusing	NULL
cells	NULL
with	NULL
control	NULL
solution	NULL
(	NULL
2	NULL
)	NULL
or	NULL
with	NULL
an	NULL
external	NULL
solution	NULL
containing	NULL
30	NULL
M	NULL
progesterone	NULL
(	NULL
3	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Whole-cell	NULL
recordings	NULL
of	NULL
swelling-activated	NULL
CI-	NULL
current	NULL
(	NULL
I	NULL
;	NULL
)	NULL
measured	NULL
during	NULL
voltage	NULL
ramps	NULL
from	NULL
-120	NULL
to	NULL
+40	NULL
mV	NULL
for	NULL
a	NULL
duration	NULL
of	NULL
200	NULL
ms	NULL
.	NULL

The	NULL
pipette	NULL
solution	NULL
contained	NULL
(	NULL
in	NULL
mM	NULL
)	NULL
140	NULL
Cs*	NULL
aspartate	NULL
,	NULL
2	NULL
MgC	NULL
)	NULL
,	NULL
4	NULL
MgATP	NULL
,	NULL
1	NULL
CaC	NULL
)	NULL
,	NULL
,	NULL
10	NULL
EGTA	NULL
,	NULL
10	NULL
Hepes	NULL
(	NULL
pH	NULL
7.2	NULL
)	NULL
.	NULL

For	NULL
the	NULL
induction	NULL
of	NULL
Iq	NULL
]	NULL
,	NULL
the	NULL
pipette	NULL
solution	NULL
was	NULL
made	NULL
hypertonic	NULL
(	NULL
390-400	NULL
mosmol	NULL
)	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
100	NULL
mM	NULL
glucose	NULL
.	NULL

Currents	NULL
are	NULL
shown	NULL
before	NULL
the	NULL
onset	NULL
of	NULL
cell	NULL
swelling	NULL
(	NULL
7	NULL
)	NULL
,	NULL
and	NULL
after	NULL
maximal	NULL
induction	NULL
of	NULL
Iq	NULL
,	NULL
while	NULL
superfusing	NULL
cells	NULL
with	NULL
control	NULL
solution	NULL
(	NULL
2	NULL
)	NULL
or	NULL
with	NULL
an	NULL
external	NULL
solution	NULL
containing	NULL
50	NULL
uM	NULL
progesterone	NULL
(	NULL
3	NULL
)	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Time-dependent	NULL
changes	NULL
in	NULL
the	NULL
slope	NULL
conductance	NULL
measured	NULL
at	NULL
the	NULL
reversal	NULL
potential	NULL
for	NULL
CI	NULL
.	NULL

terone	NULL
.	NULL

Furthermore	NULL
,	NULL
channel	NULL
inactivation	NULL
enhances	NULL
block	NULL
by	NULL
progesterone	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
state	NULL
of	NULL
the	NULL
channel	NULL
modulates	NULL
the	NULL
affinity	NULL
of	NULL
progesterone	NULL
.	NULL

In	NULL
T	NULL
cells	NULL
,	NULL
the	NULL
direct	NULL
block	NULL
of	NULL
Ky	NULL
channels	NULL
by	NULL
dihydroquinolines	NULL
and	NULL
benzhydryl	NULL
piperidines	NULL
is	NULL
also	NULL
enhanced	NULL
by	NULL
inactivation	NULL
(	NULL
41	NULL
,	NULL
42	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
progesterone	NULL
blocks	NULL
Kv1l.3	NULL
channels	NULL
exogenously	NULL
expressed	NULL
in	NULL
a	NULL
cell	NULL
line	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

Progesterone	NULL
also	NULL
blocks	NULL
other	NULL
Ky	NULL
and	NULL
Kc	NULL
,	NULL
channels	NULL
with	NULL
low	NULL
affinity	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
progesterone	NULL
blocks	NULL
K+	NULL
channels	NULL
directly	NULL
,	NULL
rather	NULL
than	NULL
acting	NULL
via	NULL
the	NULL
classical	NULL
nuclear	NULL
progesterone	NULL
receptor	NULL
pathway	NULL
.	NULL

Channel	NULL
blockade	NULL
by	NULL
progesterone	NULL
is	NULL
not	NULL
without	NULL
prece-	NULL
1600	NULL
dent	NULL
.	NULL

Previous	NULL
studies	NULL
demonstrated	NULL
that	NULL
progesterone	NULL
blocks	NULL
voltage-gated	NULL
Ca*®+	NULL
channels	NULL
in	NULL
smooth	NULL
muscle	NULL
cells	NULL
and	NULL
a	NULL
variety	NULL
of	NULL
K+	NULL
channels	NULL
in	NULL
MDCK	NULL
cells	NULL
and	NULL
hepato-cytes	NULL
(	NULL
43-45	NULL
)	NULL
.	NULL

Several	NULL
transmitter-activated	NULL
channels	NULL
are	NULL
also	NULL
suppressed	NULL
by	NULL
progesterone	NULL
in	NULL
the	NULL
micromolar	NULL
concentration	NULL
range	NULL
(	NULL
46-49	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
its	NULL
effects	NULL
on	NULL
somatic	NULL
cells	NULL
,	NULL
progesterone	NULL
activates	NULL
Ca®+*	NULL
influx	NULL
in	NULL
sperm	NULL
(	NULL
50	NULL
,	NULL
51	NULL
)	NULL
.	NULL

We	NULL
found	NULL
no	NULL
evidence	NULL
for	NULL
progesterone-induced	NULL
Ca**	NULL
influx	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Our	NULL
data	NULL
provide	NULL
the	NULL
first	NULL
evidence	NULL
that	NULL
an	NULL
endogenous	NULL
hormone	NULL
may	NULL
act	NULL
as	NULL
an	NULL
immunosuppressant	NULL
by	NULL
blocking	NULL
K*	NULL
channels	NULL
.	NULL

Inhibition	NULL
of	NULL
K*	NULL
channels	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
reduce	NULL
IL-2	NULL
production	NULL
and	NULL
T	NULL
cell	NULL
activation	NULL
in	NULL
vitro	NULL
(	NULL
22	NULL
,	NULL
23	NULL
,	NULL
52	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
recent	NULL
studies	NULL
demonstrated	NULL
that	NULL
the	NULL
peptide	NULL
scorpion	NULL
toxin	NULL
margatoxin	NULL
,	NULL
a	NULL
specific	NULL
blocker	NULL
of	NULL
Kyv1.3	NULL
channels	NULL
,	NULL
inhibits	NULL
delayed-type	NULL
hypersensitivity	NULL
reaction	NULL
and	NULL
reduces	NULL
response	NULL
to	NULL
allogeneic	NULL
challenge	NULL
in	NULL
vivo	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
depolarization	NULL
and	NULL
reduction	NULL
of	NULL
the	NULL
driving	NULL
force	NULL
for	NULL
Ca®+	NULL
entry	NULL
resulting	NULL
from	NULL
K+	NULL
channel	NULL
inhibition	NULL
are	NULL
sufficient	NULL
to	NULL
account	NULL
for	NULL
the	NULL
reduction	NULL
of	NULL
Ca	NULL
#	NULL
*	NULL
signals	NULL
and	NULL
NF-AT-driven	NULL
gene	NULL
expression	NULL
.	NULL

CRAC	NULL
channels	NULL
are	NULL
inwardly	NULL
rectifying	NULL
,	NULL
and	NULL
a	NULL
modest	NULL
depolarization	NULL
can	NULL
reduce	NULL
Ca	NULL
``	NULL
®*	NULL
entry	NULL
significantly	NULL
,	NULL
reducing	NULL
the	NULL
rise	NULL
in	NULL
below	NULL
the	NULL
threshold	NULL
for	NULL
gene	NULL
expression	NULL
(	NULL
for	NULL
a	NULL
review	NULL
,	NULL
see	NULL
reference	NULL
24	NULL
)	NULL
.	NULL

At	NULL
high	NULL
concentrations	NULL
,	NULL
progesterone	NULL
reduces	NULL
Ca®+	NULL
signaling	NULL
and	NULL
gene	NULL
expression	NULL
almost	NULL
to	NULL
control	NULL
levels	NULL
,	NULL
below	NULL
a	NULL
plateau	NULL
level	NULL
seen	NULL
with	NULL
100	NULL
nM	NULL
CTX	NULL
(	NULL
21	NULL
,	NULL
53	NULL
,	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Progesterone	NULL
,	NULL
although	NULL
acting	NULL
with	NULL
low	NULL
affinity	NULL
,	NULL
may	NULL
reduce	NULL
Ca®*	NULL
signaling	NULL
and	NULL
gene	NULL
expression	NULL
to	NULL
a	NULL
greater	NULL
extent	NULL
than	NULL
CTX	NULL
because	NULL
progesterone	NULL
also	NULL
inhibits	NULL
CTX-resistant	NULL
Ky	NULL
channels	NULL
The	NULL
block	NULL
of	NULL
K*	NULL
channels	NULL
by	NULL
progesterone	NULL
or	NULL
RU	NULL
486	NULL
can	NULL
also	NULL
account	NULL
for	NULL
previous	NULL
results	NULL
showing	NULL
that	NULL
progesterone	NULL
or	NULL
RU	NULL
486	NULL
inhibits	NULL
activation	NULL
of	NULL
human	NULL
T	NULL
cells	NULL
in	NULL
vitro	NULL
(	NULL
8	NULL
,	NULL
9	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
reduction	NULL
of	NULL
the	NULL
number	NULL
of	NULL
CD3*	NULL
cells	NULL
in	NULL
the	NULL
placenta	NULL
compared	NULL
with	NULL
maternal	NULL
blood	NULL
(	NULL
11	NULL
,	NULL
54	NULL
)	NULL
.	NULL

During	NULL
pregnancy	NULL
,	NULL
immunoregulatory	NULL
mechanisms	NULL
must	NULL
operate	NULL
locally	NULL
at	NULL
the	NULL
placental	NULL
interface	NULL
and	NULL
be	NULL
readily	NULL
reversible	NULL
to	NULL
preserve	NULL
the	NULL
systemic	NULL
immune	NULL
competence	NULL
of	NULL
the	NULL
mother	NULL
.	NULL

Several	NULL
mechanisms	NULL
involving	NULL
progesterone	NULL
may	NULL
contribute	NULL
to	NULL
fetal-maternal	NULL
protection	NULL
,	NULL
including	NULL
altered	NULL
expression	NULL
of	NULL
MHC	NULL
class	NULL
I	NULL
proteins	NULL
in	NULL
fetal	NULL
tissue	NULL
,	NULL
altered	NULL
T	NULL
cell	NULL
subsets	NULL
,	NULL
or	NULL
elaboration	NULL
of	NULL
immunosuppressive	NULL
factors	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Biochemical	NULL
measurements	NULL
have	NULL
estimated	NULL
progesterone	NULL
concentrations	NULL
to	NULL
be	NULL
20	NULL
uM	NULL
within	NULL
the	NULL
placenta	NULL
(	NULL
34	NULL
,	NULL
35	NULL
)	NULL
;	NULL
concentrations	NULL
in	NULL
the	NULL
vicinity	NULL
of	NULL
trophoblasts	NULL
producing	NULL
progesterone	NULL
must	NULL
be	NULL
even	NULL
higher	NULL
.	NULL

Average	NULL
progesterone	NULL
levels	NULL
found	NULL
in	NULL
the	NULL
placenta	NULL
would	NULL
be	NULL
sufficient	NULL
to	NULL
block	NULL
lymphocyte	NULL
K*	NULL
channels	NULL
and	NULL
thereby	NULL
mediate	NULL
a	NULL
highly	NULL
localized	NULL
and	NULL
reversible	NULL
immunosuppression	NULL
without	NULL
compromising	NULL
the	NULL
maternal	NULL
immune	NULL
system	NULL
.	NULL

The	NULL
affinity	NULL
of	NULL
progesterone	NULL
for	NULL
K*	NULL
channels	NULL
ensures	NULL
that	NULL
this	NULL
mechanism	NULL
would	NULL
only	NULL
be	NULL
effective	NULL
in	NULL
the	NULL
region	NULL
of	NULL
potential	NULL
contact	NULL
between	NULL
allogeneic	NULL
cells	NULL
,	NULL
where	NULL
progesterone	NULL
is	NULL
present	NULL
at	NULL
high	NULL
concentrations	NULL
.	NULL

Progesterone	NULL
Blocks	NULL
K*	NULL
Channels	NULL
and	NULL
T	NULL
Cell	NULL
Activation	NULL
We	NULL
thank	NULL
Dr.	NULL
Patricia	NULL
Schmidt	NULL
for	NULL
helpful	NULL
discussions	NULL
at	NULL
the	NULL
onset	NULL
of	NULL
this	NULL
project	NULL
,	NULL
Dr.	NULL
K.	NULL
George	NULL
Chandy	NULL
for	NULL
providing	NULL
clones	NULL
and	NULL
a	NULL
panel	NULL
of	NULL
stable	NULL
cell	NULL
lines	NULL
,	NULL
and	NULL
Dr.	NULL
Lu	NULL
Forrest	NULL
for	NULL
tissue	NULL
culture	NULL
support	NULL
.	NULL

This	NULL
work	NULL
is	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
grants	NULL
GM41514	NULL
and	NULL
NS14609	NULL
(	NULL
to	NULL
M.D	NULL
.	NULL

Cahalan	NULL
)	NULL
,	NULL
a	NULL
Schroedinger	NULL
Stipendium	NULL
(	NULL
to	NULL
H.H	NULL
.	NULL

Kerschbaum	NULL
)	NULL
,	NULL
and	NULL
a	NULL
fellowship	NULL
of	NULL
the	NULL
Alexander	NULL
von	NULL
Humboldt	NULL
Foun-	NULL
dation	NULL
(	NULL
to	NULL
C.	NULL
Eder	NULL
)	NULL
.	NULL

Address	NULL
correspondence	NULL
to	NULL
Michael	NULL
D.	NULL
Cahalan	NULL
,	NULL
Department	NULL
of	NULL
Physiology	NULL
and	NULL
Biophysics	NULL
,	NULL
University	NULL
of	NULL
California	NULL
,	NULL
Irvine	NULL
,	NULL
CA	NULL
92697-4560	NULL
.	NULL

Phone	NULL
:	NULL
714-824-7260	NULL
;	NULL
Fax	NULL
:	NULL
714-824-3143	NULL
;	NULL
E-mail	NULL
:	NULL
meahalan	NULL
@	NULL
uci.edu	NULL
H.H	NULL
.	NULL

Kerschbaum	NULL
's	NULL
present	NULL
address	NULL
is	NULL
Department	NULL
of	NULL
Physiology	NULL
,	NULL
Institute	NULL
for	NULL
Zoology	NULL
,	NULL
University	NULL
of	NULL
Salzburg	NULL
,	NULL
5020	NULL
Salzburg	NULL
,	NULL
Austria	NULL
Claudia	NULL
Eder	NULL
's	NULL
current	NULL
address	NULL
is	NULL
Department	NULL
of	NULL
Neurophysiology	NULL
,	NULL
Institute	NULL
of	NULL
Physiology	NULL
Humboldt	NULL
University	NULL
,	NULL
D-10019	NULL
Berlin	NULL
,	NULL
Germany	NULL
.	NULL

P.A	NULL
.	NULL

Negulescu	NULL
's	NULL
present	NULL
address	NULL
is	NULL
Aurora	NULL
Biosciences	NULL
,	NULL
11010	NULL
Torreyana	NULL
R	NULL
d.	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
92121	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
20	NULL
Apnil	NULL
1998	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
30	NULL
July	NULL
1998	NULL
.	NULL

References	NULL
1	NULL
.	NULL

2	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

Stites	NULL
,	NULL
D.P	NULL
.	NULL

,	NULL
and	NULL
P.K	NULL
.	NULL

Siiteri	NULL
.	NULL

1983	NULL
.	NULL

Steroids	NULL
as	NULL
immunosup-pressants	NULL
in	NULL
pregnancy	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

75:117-138	NULL
.	NULL

Pepe	NULL
,	NULL
G.J	NULL
.	NULL

,	NULL
and	NULL
E.D	NULL
.	NULL

Albrecht	NULL
.	NULL

1995	NULL
.	NULL

Actions	NULL
of	NULL
placental	NULL
and	NULL
fetal	NULL
adrenal	NULL
steroid	NULL
hormones	NULL
in	NULL
primate	NULL
pregnancy	NULL
.	NULL

Endo	NULL
:	NULL
Rev	NULL
.	NULL

16:608-648.	NULL
.	NULL

Beer	NULL
,	NULL
A.E	NULL
.	NULL

,	NULL
and	NULL
J.O	NULL
.	NULL

Sio	NULL
.	NULL

1982	NULL
.	NULL

Placenta	NULL
as	NULL
an	NULL
immunological	NULL
barrier	NULL
.	NULL

Biol	NULL
.	NULL

Reprod	NULL
.	NULL

26:15-27.	NULL
.	NULL

Gurka	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
R.E	NULL
.	NULL

Rocklin	NULL
.	NULL

1987	NULL
.	NULL

Reproductive	NULL
immu-	NULL
nology	NULL
.	NULL

AMA	NULL
(	NULL
J	NULL
.	NULL

Am	NULL
.	NULL

Med	NULL
.	NULL

Assoc	NULL
)	NULL
.	NULL

258:2983-2987.	NULL
.	NULL

Hunt	NULL
,	NULL
J.S	NULL
.	NULL

1994	NULL
.	NULL

Immunologically	NULL
relevant	NULL
cells	NULL
in	NULL
the	NULL
uterus	NULL
.	NULL

Biol	NULL
.	NULL

Reprod	NULL
.	NULL

50:461-466.	NULL
.	NULL

Siiteri	NULL
,	NULL
P.K	NULL
.	NULL

,	NULL
F.	NULL
Febres	NULL
,	NULL
LE	NULL
.	NULL

Clemens	NULL
,	NULL
R.J.	NULL
Chang	NULL
,	NULL
B.	NULL
Gon-	NULL
dos	NULL
,	NULL
and	NULL
D.	NULL
Stites	NULL
1977	NULL
.	NULL

Progesterone	NULL
and	NULL
maintenance	NULL
of	NULL
pregnancy	NULL
:	NULL
is	NULL
progesterone	NULL
nature	NULL
's	NULL
immunosuppressant	NULL
?	NULL

Ann	NULL
.	NULL

NY	NULL
Aad	NULL
.	NULL

Sa	NULL
.	NULL

286:384-397.	NULL
.	NULL

Siiteri	NULL
,	NULL
P.K	NULL
.	NULL

,	NULL
and	NULL
D.P	NULL
.	NULL

Stites	NULL
.	NULL

1982	NULL
.	NULL

Immunologic	NULL
and	NULL
endo-	NULL
crine	NULL
interrelationships	NULL
in	NULL
pregnancy	NULL
.	NULL

Biol	NULL
.	NULL

Reprod	NULL
.	NULL

26:1-14.	NULL
.	NULL

Clemens	NULL
,	NULL
LE	NULL
.	NULL

,	NULL
P.K	NULL
.	NULL

Siiteri	NULL
,	NULL
and	NULL
D.P	NULL
.	NULL

Stites	NULL
1979	NULL
.	NULL

Mecha-	NULL
nism	NULL
of	NULL
immunosuppression	NULL
of	NULL
progesterone	NULL
on	NULL
maternal	NULL
lymphocyte	NULL
activation	NULL
during	NULL
pregnancy	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

122	NULL
:	NULL
1978-1985.	NULL
.	NULL

Van	NULL
Voorhis	NULL
,	NULL
B.J	NULL
.	NULL

,	NULL
D.J	NULL
.	NULL

Anderson	NULL
,	NULL
and	NULL
J.A	NULL
.	NULL

Hill	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
RU	NULL
486	NULL
on	NULL
immune	NULL
function	NULL
and	NULL
steroid-induced	NULL
immunosuppression	NULL
in	NULL
vito	NULL
.	NULL

J	NULL
Clin	NULL
.	NULL

:	NULL
Endoainol	NULL
.	NULL

Metab	NULL
.	NULL

69	NULL
:	NULL
1195-1199	NULL
.	NULL

Monterroso	NULL
,	NULL
V.H	NULL
.	NULL

,	NULL
and	NULL
P.J	NULL
.	NULL

Hansen	NULL
.	NULL

1993	NULL
.	NULL

R	NULL
egulation	NULL
of	NULL
bovine	NULL
and	NULL
ovine	NULL
lymphocyte	NULL
proliferation	NULL
by	NULL
progesterone	NULL
:	NULL
modulation	NULL
by	NULL
steroid	NULL
receptor	NULL
antagonists	NULL
and	NULL
physiological	NULL
status	NULL
.	NULL

A	NULL
da	NULL
Endoainol	NULL
.	NULL

129:532-535	NULL
.	NULL

Pavia	NULL
,	NULL
C.	NULL
,	NULL
P.K	NULL
.	NULL

Siiteri	NULL
,	NULL
J.D	NULL
.	NULL

Perlman	NULL
,	NULL
and	NULL
D.P	NULL
.	NULL

Stites	NULL
.	NULL

1979	NULL
.	NULL

Suppression	NULL
of	NULL
murine	NULL
allogeneic	NULL
cell	NULL
interactions	NULL
by	NULL
sex	NULL
hor-mones	NULL
.	NULL

J	NULL
Reprod	NULL
.	NULL

Immunol	NULL
.	NULL

1:33-38	NULL
.	NULL

Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

,	NULL
and	NULL
N.A	NULL
.	NULL

Clipstone	NULL
.	NULL

1994	NULL
.	NULL

Signal	NULL
transmission	NULL
between	NULL
the	NULL
plasma	NULL
membrane	NULL
and	NULL
nucleus	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

63:1045-1083	NULL
.	NULL

Negulescu	NULL
,	NULL
P.A	NULL
.	NULL

,	NULL
N.	NULL
Shastri	NULL
,	NULL
and	NULL
M.D	NULL
.	NULL

Cahalan	NULL
.	NULL

1994	NULL
.	NULL

Intracellular	NULL
calcium	NULL
dependence	NULL
of	NULL
gene	NULL
expression	NULL
in	NULL
single	NULL
T	NULL
lymphocytes	NULL
.	NULL

Proc	NULL
Natl	NULL
.	NULL

Aad	NULL
.	NULL

Sa	NULL
.	NULL

USA	NULL
.	NULL

91:2873-2877	NULL
.	NULL

Lewis	NULL
,	NULL
R.S	NULL
.	NULL

,	NULL
and	NULL
M.D	NULL
.	NULL

Cahalan	NULL
.	NULL

1995	NULL
.	NULL

Potassium	NULL
and	NULL
calcium	NULL
channels	NULL
in	NULL
lymphocytes	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

13:623-653	NULL
.	NULL

Timmerman	NULL
,	NULL
L.A.	NULL
,	NULL
N.A	NULL
.	NULL

Clipstone	NULL
,	NULL
S.N	NULL
.	NULL

Ho	NULL
,	NULL
J.P.	NULL
Northrop	NULL
,	NULL
and	NULL
G.R	NULL
.	NULL

Crabtree	NULL
.	NULL

1996	NULL
.	NULL

Rapid	NULL
shuttling	NULL
of	NULL
NF-AT	NULL
in	NULL
dis	NULL
1601	NULL
Ehring	NULL
et	NULL
al	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26.	NULL
crimination	NULL
of	NULL
Ca**	NULL
signals	NULL
and	NULL
immunosuppression	NULL
.	NULL

Nature	NULL
.	NULL

383:837-840	NULL
.	NULL

Dolmetsch	NULL
,	NULL
R.E	NULL
.	NULL

,	NULL
R.S	NULL
.	NULL

Lewis	NULL
,	NULL
C.C	NULL
.	NULL

Goodnow	NULL
,	NULL
and	NULL
JI	NULL
.	NULL

Healy	NULL
.	NULL

1997	NULL
.	NULL

Differential	NULL
activation	NULL
of	NULL
transcription	NULL
factors	NULL
induced	NULL
by	NULL
Ca**	NULL
response	NULL
amplitude	NULL
and	NULL
duration	NULL
.	NULL

Natwre	NULL
.	NULL

386:855-858	NULL
.	NULL

Lewis	NULL
,	NULL
R.S	NULL
.	NULL

,	NULL
and	NULL
M.D	NULL
.	NULL

Cahalan	NULL
.	NULL

1989	NULL
.	NULL

Mitogen-induced	NULL
os	NULL
cillations	NULL
of	NULL
cytosolic	NULL
Ca**	NULL
and	NULL
transmembrane	NULL
Ca®+*	NULL
current	NULL
in	NULL
human	NULL
leukemic	NULL
T	NULL
cells	NULL
.	NULL

Cell	NULL
Regul	NULL
.	NULL

1:99-112	NULL
.	NULL

Zweifach	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
R.S	NULL
.	NULL

Lewis	NULL
1993	NULL
.	NULL

Mitogen-regulated	NULL
current	NULL
of	NULL
T	NULL
lymphocytes	NULL
is	NULL
activated	NULL
by	NULL
depletion	NULL
of	NULL
intracellular	NULL
stores	NULL
.	NULL

Proc	NULL
Natl	NULL
.	NULL

Aard	NULL
.	NULL

Sa	NULL
.	NULL

USA	NULL
.	NULL

90:6295-6299	NULL
.	NULL

Premack	NULL
,	NULL
B.A	NULL
.	NULL

,	NULL
T.V	NULL
.	NULL

McDonald	NULL
,	NULL
and	NULL
P.	NULL
Gardner	NULL
.	NULL

1994	NULL
.	NULL

Activation	NULL
of	NULL
Ca®+	NULL
current	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
following	NULL
the	NULL
depletion	NULL
of	NULL
Ca®*	NULL
stores	NULL
by	NULL
microsomal	NULL
Ca®*-ATPase	NULL
inhibitors	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

152:5226-5240	NULL
.	NULL

Phipps	NULL
,	NULL
D.J	NULL
.	NULL

,	NULL
D.R	NULL
.	NULL

Branch	NULL
,	NULL
and	NULL
LC	NULL
.	NULL

Schlichter	NULL
.	NULL

1996	NULL
.	NULL

Chlo-ride-channel	NULL
block	NULL
inhibits	NULL
T	NULL
lymphocyte	NULL
activation	NULL
and	NULL
signalling	NULL
.	NULL

Cell	NULL
.	NULL

Signalling	NULL
.	NULL

8:141-149	NULL
.	NULL

Kerschbaum	NULL
,	NULL
H.H	NULL
.	NULL

,	NULL
P.A	NULL
.	NULL

Negulescu	NULL
,	NULL
and	NULL
M.D	NULL
.	NULL

Cahalan	NULL
.	NULL

1997	NULL
.	NULL

Ion	NULL
channels	NULL
,	NULL
Ca®*	NULL
signaling	NULL
,	NULL
and	NULL
reporter	NULL
gene	NULL
expression	NULL
in	NULL
antigen-specific	NULL
mouse	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

159:1628-1638	NULL
.	NULL

Chandy	NULL
,	NULL
KG	NULL
.	NULL

,	NULL
T.E	NULL
.	NULL

DeCoursey	NULL
,	NULL
M.D	NULL
.	NULL

Cahalan	NULL
,	NULL
C.	NULL
McLaughlin	NULL
,	NULL
and	NULL
S.	NULL
Gupta	NULL
.	NULL

1984	NULL
.	NULL

Voltage-gated	NULL
potassium	NULL
channels	NULL
are	NULL
required	NULL
for	NULL
human	NULL
T	NULL
lymphocyte	NULL
activation	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

160:369-385	NULL
.	NULL

Lin	NULL
,	NULL
C.S	NULL
.	NULL

,	NULL
R.C	NULL
.	NULL

Boltz	NULL
,	NULL
J.T	NULL
.	NULL

Blake	NULL
,	NULL
M.	NULL
Nguyen	NULL
,	NULL
A.	NULL
Talento	NULL
,	NULL
P.A	NULL
.	NULL

Fischer	NULL
,	NULL
M.S	NULL
.	NULL

Springer	NULL
,	NULL
N.H.	NULL
Sigal	NULL
,	NULL
R.S	NULL
.	NULL

Slaughter	NULL
,	NULL
and	NULL
ML	NULL
.	NULL

Garcia	NULL
.	NULL

1993	NULL
.	NULL

Voltage-gated	NULL
potassium	NULL
channels	NULL
regulate	NULL
calcium-dependent	NULL
pathways	NULL
involved	NULL
in	NULL
human	NULL
T	NULL
lymphocyte	NULL
activation	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

177:637-645	NULL
.	NULL

Cahalan	NULL
,	NULL
M.D	NULL
.	NULL

,	NULL
and	NULL
K.G	NULL
.	NULL

Chandy	NULL
.	NULL

1997	NULL
.	NULL

Ion	NULL
channels	NULL
in	NULL
the	NULL
immune	NULL
system	NULL
as	NULL
targets	NULL
for	NULL
immunosuppression	NULL
.	NULL

Cur	NULL
Opin	NULL
.	NULL

Biotechnol	NULL
.	NULL

8:749-756	NULL
.	NULL

Koo	NULL
,	NULL
G.C	NULL
.	NULL

,	NULL
J.T	NULL
.	NULL

Blake	NULL
,	NULL
A.	NULL
Talento	NULL
,	NULL
M.	NULL
Nguyen	NULL
,	NULL
S.	NULL
Lin	NULL
,	NULL
A.	NULL
Sirotina	NULL
,	NULL
K.	NULL
Shah	NULL
,	NULL
K.	NULL
Mulvany	NULL
,	NULL
D.J	NULL
.	NULL

Hora	NULL
,	NULL
P.	NULL
Cunningham	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
.	NULL

Blockade	NULL
of	NULL
the	NULL
voltage-gated	NULL
potassium	NULL
channel	NULL
Kvl.3	NULL
inhibits	NULL
immune	NULL
responses	NULL
in	NULL
vivo	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

158	NULL
:	NULL
5120-5128	NULL
.	NULL

Karttunen	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
N.	NULL
Shastri	NULL
.	NULL

1991	NULL
.	NULL

Measurement	NULL
of	NULL
ligand-	NULL
27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40.	NULL
induced	NULL
activation	NULL
in	NULL
single	NULL
viable	NULL
T	NULL
cells	NULL
using	NULL
the	NULL
lacZ	NULL
reporter	NULL
gene	NULL
element	NULL
of	NULL
the	NULL
human	NULL
interleukin	NULL
2	NULL
enhancer	NULL
.	NULL

Proc	NULL
Natl	NULL
.	NULL

Aad	NULL
.	NULL

Sa	NULL
.	NULL

USA	NULL
.	NULL

88:3972-3976	NULL
.	NULL

Shastri	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
F.	NULL
Gonzalez	NULL
.	NULL

1993	NULL
.	NULL

Endogenous	NULL
generation	NULL
and	NULL
presentation	NULL
of	NULL
the	NULL
ovalbumin	NULL
peptide/	NULL
K®°	NULL
complex	NULL
to	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

150:2724-2736	NULL
.	NULL

Cahalan	NULL
,	NULL
M.D	NULL
.	NULL

,	NULL
K.G	NULL
.	NULL

Chandy	NULL
,	NULL
T.E	NULL
.	NULL

DeCoursey	NULL
,	NULL
and	NULL
S.	NULL
Gupta	NULL
.	NULL

1985	NULL
.	NULL

A	NULL
voltage-gated	NULL
potassium	NULL
channel	NULL
in	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

J	NULL
Physiol	NULL
.	NULL

(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

358:197-237	NULL
.	NULL

Fiering	NULL
,	NULL
S.N	NULL
.	NULL

,	NULL
M.	NULL
Roederer	NULL
,	NULL
G.P	NULL
.	NULL

Nolan	NULL
,	NULL
D.R	NULL
.	NULL

Micklem	NULL
,	NULL
D.R	NULL
.	NULL

Parks	NULL
,	NULL
and	NULL
L.A.	NULL
Herzenberg	NULL
.	NULL

1991	NULL
.	NULL

Improved	NULL
FACS-Gal	NULL
:	NULL
flow	NULL
cytometric	NULL
analysis	NULL
and	NULL
sorting	NULL
of	NULL
viable	NULL
eukaryotic	NULL
cells	NULL
expressing	NULL
reporter	NULL
gene	NULL
constructs	NULL
.	NULL

Cytometry	NULL
.	NULL

12:291-301	NULL
.	NULL

Hamill	NULL
,	NULL
O	NULL
.P	NULL
.	NULL

,	NULL
A.	NULL
Marty	NULL
,	NULL
E.	NULL
Neher	NULL
,	NULL
B.	NULL
Sakmann	NULL
,	NULL
and	NULL
F.J.	NULL
Sig-worth	NULL
.	NULL

1981	NULL
.	NULL

Improved	NULL
patch-clamp	NULL
techniques	NULL
for	NULL
high-res	NULL
olution	NULL
current	NULL
recording	NULL
from	NULL
cells	NULL
and	NULL
cell-free	NULL
membrane	NULL
patches	NULL
.	NULL

Pfliigers	NULL
Arch	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Physiol	NULL
.	NULL

391:85-100	NULL
.	NULL

Horn	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
A.	NULL
Marty	NULL
.	NULL

1988	NULL
.	NULL

Muscarinic	NULL
activation	NULL
of	NULL
ionic	NULL
currents	NULL
measured	NULL
by	NULL
a	NULL
new	NULL
whole-cell	NULL
recording	NULL
method	NULL
.	NULL

J	NULL
Gen.	NULL
Physiol	NULL
.	NULL

92:145-159	NULL
.	NULL

Grynkiewicz	NULL
,	NULL
G.	NULL
,	NULL
M.	NULL
Poenie	NULL
,	NULL
and	NULL
R.Y	NULL
.	NULL

Tsien	NULL
.	NULL

1985	NULL
.	NULL

A	NULL
new	NULL
generation	NULL
of	NULL
Ca®+*	NULL
indicators	NULL
with	NULL
greatly	NULL
improved	NULL
fluorescence	NULL
properties	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

260:3440-3450	NULL
.	NULL

Thastrup	NULL
,	NULL
O.	NULL
,	NULL
AP	NULL
.	NULL

Dawson	NULL
,	NULL
O.	NULL
Scharff	NULL
,	NULL
B.	NULL
Foder	NULL
,	NULL
P.J	NULL
.	NULL

Cullen	NULL
,	NULL
B.K	NULL
.	NULL

Drobak	NULL
,	NULL
P.J	NULL
.	NULL

Bjerrum	NULL
,	NULL
S	NULL
$	NULL
.B	NULL
.	NULL

Christensen	NULL
,	NULL
and	NULL
MR.	NULL
Hanley	NULL
.	NULL

1989	NULL
.	NULL

Thapsigargin	NULL
,	NULL
a	NULL
novel	NULL
molecular	NULL
probe	NULL
for	NULL
studying	NULL
intracellular	NULL
calcium	NULL
release	NULL
and	NULL
storage	NULL
.	NULL

A	NULL
gents	NULL
Actions	NULL
.	NULL

27:17-23	NULL
.	NULL

Runnebaum	NULL
,	NULL
B.	NULL
,	NULL
H.	NULL
Runnebaum	NULL
,	NULL
I.	NULL
Stober	NULL
,	NULL
and	NULL
J.	NULL
Zander	NULL
.	NULL

1975	NULL
.	NULL

Progesterone	NULL
20	NULL
alpha-dihydroprogesterone	NULL
and	NULL
20	NULL
beta-dihydroprogesterone	NULL
levels	NULL
in	NULL
different	NULL
compartments	NULL
from	NULL
the	NULL
human	NULL
foeto-placental	NULL
unit	NULL
.	NULL

Ada	NULL
Endoaginol	NULL
.	NULL

80	NULL
:	NULL
558-568	NULL
.	NULL

Runnebaum	NULL
,	NULL
B.	NULL
,	NULL
I.	NULL
Stober	NULL
,	NULL
and	NULL
J.	NULL
Zander	NULL
.	NULL

1975	NULL
.	NULL

Progesterone	NULL
,	NULL
20	NULL
alpha-dihydroprogesterone	NULL
and	NULL
20	NULL
beta-dihydroprogesterone	NULL
in	NULL
mother	NULL
and	NULL
child	NULL
at	NULL
birth	NULL
.	NULL

A	NULL
ga	NULL
Endoainol	NULL
.	NULL

80	NULL
:	NULL
569-576	NULL
.	NULL

Gouy	NULL
,	NULL
H.	NULL
,	NULL
D.	NULL
Cefai	NULL
,	NULL
S.B	NULL
.	NULL

Christensen	NULL
,	NULL
P.	NULL
Debre	NULL
,	NULL
and	NULL
G.	NULL
Bis	NULL
muth	NULL
.	NULL

1990	NULL
.	NULL

Ca®*	NULL
influx	NULL
in	NULL
human	NULL
T	NULL
lymphocytes	NULL
is	NULL
induced	NULL
independently	NULL
of	NULL
inositol	NULL
phosphate	NULL
production	NULL
by	NULL
mobilization	NULL
of	NULL
intracellular	NULL
Ca	NULL
?	NULL

*	NULL
stores	NULL
.	NULL

A	NULL
study	NULL
with	NULL
the	NULL
Ca®+	NULL
endoplasmic	NULL
reticulum-	NULL
ATPase	NULL
inhibitor	NULL
thapsigargin	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
.	NULL

20:2269-2275	NULL
.	NULL

Mason	NULL
,	NULL
M.J.	NULL
,	NULL
M.P	NULL
.	NULL

Mahaut-Smith	NULL
,	NULL
and	NULL
S.	NULL
Grinstein	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
role	NULL
of	NULL
intracellular	NULL
Ca®+*	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
plasma	NULL
membrane	NULL
permeability	NULL
of	NULL
unstimulated	NULL
rat	NULL
lymphocytes	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266:10872-10879	NULL
.	NULL

Verheugen	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
H.P	NULL
.	NULL

Vijverberg	NULL
,	NULL
M.	NULL
Oortgiesen	NULL
,	NULL
and	NULL
M.D	NULL
.	NULL

Cahalan	NULL
.	NULL

1995	NULL
.	NULL

Voltage-gated	NULL
and	NULL
Ca**-activated	NULL
K*	NULL
channels	NULL
in	NULL
intact	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

Noninvasive	NULL
measurements	NULL
of	NULL
membrane	NULL
currents	NULL
,	NULL
membrane	NULL
potential	NULL
,	NULL
and	NULL
intracellular	NULL
calcium	NULL
.	NULL

J	NULL
Gen.	NULL
Physiol	NULL
.	NULL

105:765-794	NULL
.	NULL

Logsdon	NULL
,	NULL
N.J.	NULL
,	NULL
J.	NULL
Kang	NULL
,	NULL
J.A	NULL
.	NULL

Togo	NULL
,	NULL
EP	NULL
.	NULL

Christian	NULL
,	NULL
and	NULL
J.	NULL
Ai-yar	NULL
.	NULL

1997	NULL
.	NULL

A	NULL
novel	NULL
gene	NULL
,	NULL
hKCa4	NULL
,	NULL
encodes	NULL
the	NULL
calcium-activated	NULL
potassium	NULL
channel	NULL
in	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272:32723-32726	NULL
.	NULL

Revelli	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Massobrio	NULL
,	NULL
and	NULL
J.	NULL
Tesarik	NULL
.	NULL

1998	NULL
.	NULL

Nongenomic	NULL
actions	NULL
of	NULL
steroid	NULL
hormones	NULL
in	NULL
reproductive	NULL
tissues	NULL
.	NULL

1602	NULL
41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

Endog	NULL
.	NULL

Rev	NULL
.	NULL

19:3-17	NULL
.	NULL

Michne	NULL
,	NULL
W.F	NULL
.	NULL

,	NULL
JW	NULL
.	NULL

Guiles	NULL
,	NULL
A.M.	NULL
Treasurywala	NULL
,	NULL
LA	NULL
.	NULL

Cas-tonguay	NULL
,	NULL
C.A	NULL
.	NULL

Weigelt	NULL
,	NULL
B.	NULL
Oconnor	NULL
,	NULL
W.A	NULL
.	NULL

Volberg	NULL
,	NULL
A.M.	NULL
Grant	NULL
,	NULL
C.C	NULL
.	NULL

Chadwick	NULL
,	NULL
and	NULL
D.S	NULL
.	NULL

Krafte	NULL
.	NULL

1995	NULL
.	NULL

Novel	NULL
inhibi-tors	NULL
of	NULL
potassium	NULL
ion	NULL
channels	NULL
on	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

J	NULL
Med	NULL
.	NULL

Chem	NULL
.	NULL

38:1877-1883	NULL
.	NULL

Nguyen	NULL
,	NULL
A.	NULL
,	NULL
J.C.	NULL
Kath	NULL
,	NULL
D.C.	NULL
Hanson	NULL
,	NULL
M.S	NULL
.	NULL

Biggers	NULL
,	NULL
P.C	NULL
.	NULL

Canniff	NULL
,	NULL
C.B	NULL
.	NULL

Donovan	NULL
,	NULL
R.J.	NULL
Mather	NULL
,	NULL
M.J.	NULL
Bruns	NULL
,	NULL
H.	NULL
Rauer	NULL
,	NULL
J.	NULL
Aiyar	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
.	NULL

Novel	NULL
nonpeptide	NULL
agents	NULL
potently	NULL
block	NULL
the	NULL
C-type	NULL
inactivated	NULL
conformation	NULL
of	NULL
Kv1.3	NULL
and	NULL
suppress	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Mol	NULL
.	NULL

Pharmacol	NULL
.	NULL

50:1672-1679	NULL
.	NULL

Bielefeldt	NULL
,	NULL
K.	NULL
,	NULL
L.	NULL
Waite	NULL
,	NULL
FM	NULL
.	NULL

Abboud	NULL
,	NULL
and	NULL
JL	NULL
.	NULL

Conklin	NULL
.	NULL

1996	NULL
.	NULL

Nongenomic	NULL
effects	NULL
of	NULL
progesterone	NULL
on	NULL
human	NULL
intestinal	NULL
smooth	NULL
muscle	NULL
cells	NULL
.	NULL

Am	NULL
.	NULL

J	NULL
Physiol	NULL
.	NULL

271	NULL
:	NULL
G6370-G376	NULL
.	NULL

Waldegger	NULL
,	NULL
S.	NULL
,	NULL
F.	NULL
Beisse	NULL
,	NULL
H.	NULL
Apfel	NULL
,	NULL
S.	NULL
Breit	NULL
,	NULL
H.A	NULL
.	NULL

Kolb	NULL
,	NULL
D.	NULL
Haussinger	NULL
,	NULL
and	NULL
F.	NULL
Lang	NULL
.	NULL

1995	NULL
.	NULL

Electrophysiological	NULL
effects	NULL
of	NULL
progesterone	NULL
on	NULL
hepatocytes	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Ada	NULL
.	NULL

1266	NULL
:	NULL
186-190	NULL
.	NULL

Breit	NULL
,	NULL
S.	NULL
,	NULL
H.	NULL
Kolb	NULL
,	NULL
H.	NULL
Apfel	NULL
,	NULL
C.	NULL
Haberland	NULL
,	NULL
M.	NULL
Schmitt	NULL
,	NULL
D.	NULL
Heaussinger	NULL
,	NULL
J.	NULL
Graf	NULL
,	NULL
and	NULL
F.	NULL
Lang	NULL
.	NULL

1998	NULL
.	NULL

Regulation	NULL
of	NULL
ion	NULL
channels	NULL
in	NULL
rat	NULL
hepatocytes	NULL
.	NULL

Pfliigers	NULL
A	NULL
rth	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Physiol	NULL
.	NULL

435	NULL
:	NULL
203-210	NULL
.	NULL

Wu	NULL
,	NULL
F.S	NULL
.	NULL

,	NULL
TT	NULL
.	NULL

Gibbs	NULL
,	NULL
and	NULL
D.H.	NULL
Farb	NULL
.	NULL

1990	NULL
.	NULL

Inverse	NULL
modulation	NULL
of	NULL
gamma-aminobutyric	NULL
acid-	NULL
and	NULL
glycine-induced	NULL
currents	NULL
by	NULL
progesterone	NULL
.	NULL

Mol	NULL
.	NULL

Pharmacol	NULL
.	NULL

37:597-602	NULL
.	NULL

Bertrand	NULL
,	NULL
D.	NULL
,	NULL
S.	NULL
Valera	NULL
,	NULL
S.	NULL
Bertrand	NULL
,	NULL
M.	NULL
Ballivet	NULL
,	NULL
and	NULL
D.	NULL
Rungger	NULL
.	NULL

1991	NULL
.	NULL

Steroids	NULL
inhibit	NULL
nicotinic	NULL
acetylcholine	NULL
receptors	NULL
.	NULL

Neurvreport	NULL
.	NULL

2:277-280	NULL
.	NULL

Valera	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
Ballivet	NULL
,	NULL
and	NULL
D.	NULL
Bertrand	NULL
.	NULL

1992	NULL
.	NULL

Progesterone	NULL
modulates	NULL
a	NULL
neuronal	NULL
nicotinic	NULL
acetylcholine	NULL
receptor	NULL
.	NULL

Proc	NULL
Natl	NULL
.	NULL

Aad	NULL
.	NULL

Sa	NULL
.	NULL

USA	NULL
.	NULL

$	NULL
9:9949-9953	NULL
.	NULL

Bergeron	NULL
,	NULL
R.	NULL
,	NULL
C.	NULL
de	NULL
Montigny	NULL
,	NULL
and	NULL
G.	NULL
Debonnel	NULL
.	NULL

1996	NULL
.	NULL

Po-tentiation	NULL
of	NULL
neuronal	NULL
NMDA	NULL
response	NULL
induced	NULL
by	NULL
dehy-droepiandrosterone	NULL
and	NULL
its	NULL
suppression	NULL
by	NULL
progesterone	NULL
:	NULL
effects	NULL
mediated	NULL
via	NULL
sigma	NULL
receptors	NULL
.	NULL

J	NULL
Newosd	NULL
.	NULL

16:1193-1202	NULL
.	NULL

Foresta	NULL
,	NULL
C.	NULL
,	NULL
M.	NULL
Rossato	NULL
,	NULL
and	NULL
F.	NULL
Di	NULL
Virgilio	NULL
.	NULL

1993	NULL
.	NULL

Ion	NULL
fluxes	NULL
through	NULL
the	NULL
progesterone-activated	NULL
channel	NULL
of	NULL
the	NULL
sperm	NULL
plasma	NULL
membrane	NULL
.	NULL

Biochem	NULL
.	NULL

J	NULL
.	NULL

294:279-283	NULL
.	NULL

Blackmore	NULL
,	NULL
P.F	NULL
.	NULL

1993	NULL
.	NULL

Rapid	NULL
non-genomic	NULL
actions	NULL
of	NULL
progesterone	NULL
stimulate	NULL
influx	NULL
and	NULL
the	NULL
acrosome	NULL
reaction	NULL
in	NULL
human	NULL
sperm	NULL
.	NULL

Cell	NULL
.	NULL

Signalling	NULL
5:531-538	NULL
.	NULL

Price	NULL
,	NULL
M.	NULL
,	NULL
S.C.	NULL
Lee	NULL
,	NULL
and	NULL
C.	NULL
Deutsch	NULL
.	NULL

1989	NULL
.	NULL

Charybdotoxin	NULL
inhibits	NULL
proliferation	NULL
and	NULL
interleukin	NULL
2	NULL
production	NULL
in	NULL
human	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
.	NULL

Proc	NULL
Natl	NULL
.	NULL

Aad	NULL
.	NULL

Sa	NULL
.	NULL

USA	NULL
.	NULL

86	NULL
:	NULL
10171-10175	NULL
.	NULL

Hess	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
Oortgiesen	NULL
,	NULL
and	NULL
M.D	NULL
.	NULL

Cahalan	NULL
.	NULL

1993	NULL
.	NULL

Calcium	NULL
oscillations	NULL
in	NULL
human	NULL
T	NULL
and	NULL
natural	NULL
killer	NULL
cells	NULL
depend	NULL
upon	NULL
membrane	NULL
potential	NULL
and	NULL
calcium	NULL
influx	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

150	NULL
:	NULL
2620-2633	NULL
.	NULL

Roussev	NULL
,	NULL
R.G	NULL
.	NULL

,	NULL
N.G	NULL
.	NULL

Higgins	NULL
,	NULL
and	NULL
J.A	NULL
.	NULL

McIntyre	NULL
.	NULL

1993	NULL
.	NULL

Phenotypic	NULL
characterization	NULL
of	NULL
normal	NULL
human	NULL
placental	NULL
mononuclear	NULL
cells	NULL
.	NULL

J	NULL
Reprod	NULL
.	NULL

Immunol	NULL
.	NULL

25:15-29	NULL
.	NULL

Grissmer	NULL
,	NULL
S.	NULL
,	NULL
A.N	NULL
.	NULL

Nguyen	NULL
,	NULL
J.	NULL
Aiyar	NULL
,	NULL
D.C.	NULL
Hanson	NULL
,	NULL
R.J.	NULL
Mather	NULL
,	NULL
G.A	NULL
.	NULL

Gutman	NULL
,	NULL
M.J.	NULL
Karmilowicz	NULL
,	NULL
D.D	NULL
.	NULL

Auperin	NULL
,	NULL
and	NULL
K.G	NULL
.	NULL

Chandy	NULL
.	NULL

1994	NULL
.	NULL

Pharmacological	NULL
characterization	NULL
of	NULL
five	NULL
cloned	NULL
voltage-gated	NULL
K*	NULL
channels	NULL
,	NULL
types	NULL
Kvl.1	NULL
,	NULL
1.2	NULL
,	NULL
1.3	NULL
,	NULL
1.5	NULL
,	NULL
and	NULL
3.1	NULL
,	NULL
stably	NULL
expressed	NULL
in	NULL
mammalian	NULL
cell	NULL
lines	NULL
.	NULL

Mol	NULL
.	NULL

Pharmacol	NULL
.	NULL

45:1227-1234	NULL
.	NULL

Progesterone	NULL
Blocks	NULL
K*	NULL
Channels	NULL
and	NULL
T	NULL
Cell	NULL
Activation	NULL

